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The Role of TGF-β in CTB-Insulin Regulated Human Dendritic Cell Tolerance 
by 
Grace Edosewe Esebanmen 
Doctor of Philosophy, Graduate Program in Biology 
Loma Linda University, June 2017 
Dr. William H. R Langridge 
Cholera toxin B subunit fusion to autoantigen vaccines such as proinsulin (CTB-
INS) down regulates dendritic cell (DC) activation and induces the synthesis of DC 
immunosuppressive cytokines. Recent studies of CTB-INS induction of immune 
tolerance in human DCs indicate that increased IDO1 biosynthesis may play an important 
role in CTB-INS vaccine inhibition of DC activation.  Previous studies suggest 
transforming growth factor beta (TGF-β) may play a role in the stimulation of IDO1 
biosynthesis for induction of immunological tolerance in murine DCs. To elucidate the 
mechanisms by which CTB-INS may stimulate IDO1 biosynthesis and mediate tolerance 
in human DCs, we investigated the contribution of TGF-β superfamily ligand proteins to 
CTB-INS induction of IDO biosynthesis in human monocyte-derived DCs (moDCs). Our 
previous studies demonstrated that CTB-INS activates the non-canonical NF-κB pathway 
to induce IDO1 biosynthesis in human DCs. However, experiments presented in this 
dissertation demonstrate that the CTB-INS fusion protein also stimulates biosynthesis of 
the immunoregulatory molecules TGF-β1, activin-A and integrin αvβ8 a molecule known 
to activate TGF-β1. In addition, CTB-INS stimulates increased levels of Smad2/3 
phosphorylation in the vaccinated DCs. Further, we confirmed that CTB-INS 
upregulation of the TGF-β superfamily is unrelated to IDO1 biosynthesis in human 
 xvii 
moDCs. In conclusion, our experimental findings identified novel immunoregulatory 
functions of CTB-INS fusion protein and suggest the fusion protein may utilize 
previously unidentified mechanisms for the regulation of human DC activation to 
mediate tolerance, a significant finding for development of clinical applications in the 
therapy of tissue specific autoimmunity.  
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CHAPTER ONE 
INTRODUCTION: AUTOIMMUNITY, STRATEGIES FOR THERAPY, 
TOLEROGENIC DENDRITIC CELLS 
 
Autoimmune Diseases and Type 1 Diabetes 
Autoimmunity is the break-down of immunological mechanisms that control the 
function of the immune system. Autoimmunity is characterized by immune cell attack on 
self-tissues that lead to the development of a chronic inflammatory diseased state (Freitag 
et al., 2016). Autoimmune diseases affect greater than 5 percent of the worldwide 
population and in recent years, the incidences of autoimmune diseases have increased 
dramatically. The conditions of autoimmune disease are profoundly debilitating, limiting, 
cause severe discomfort and result in a significant reduction in longevity, and can lead to 
severe socio-economic deprivation (Freitag et al., 2016; Kamradt  and Mitchison 2001).  
The classical mechanism for initiation of autoimmunity involves the presentation 
of peptides from self-antigens on MHC-II molecules by activated antigen presenting cells 
(APCs) such as dendritic cells (DCs) to self-reactive T cells leading to the activation and 
proliferation of T cells. Further expression of adhesion molecules and chemokine factors 
by activated T cells enable homing and infiltration of target tissues. Subsequently, the 
autoreactive effector T cells induce inflammation and immune-mediated destruction of 
the target tissues (Benson et al., 2014; Benson et al., 2010; Roncarolo and Battaglia, 
2007). 
Autoimmune conditions can be generally classified into two categories: 
autoimmune disorders that lead to the destruction of several tissues or organs are 
described as systemic autoimmune diseases and examples of such are rheumatoid 
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arthritis, systemic lupus erythematosus and scleroderma; the other class of autoimmune 
process directly damages specific tissues or organ and are labeled tissue-specific 
autoimmune diseases. They include Type 1 diabetes (T1D), Hashimoto’s thyroiditis and 
multiple sclerosis (MS) (Van Brussel et al., 2014). T1D is a chronic autoimmune disease 
that develops from the destruction of the islet β cells of the pancreas as mediated by 
effector T cells, leading to total insulin deficiency. A trio of genetic predisposition, 
epigenetic, and environmental factors have been implicated as causes for the condition 
(Stankov et al., 2013). Epidemiological studies reveal a general increase in autoimmune 
disease incidence of about 3%, with approximately 65,000 new cases of T1D documented 
every year in children less than 15 years of age (Borchers et al., 2010; Stankov et al., 
2013). The destructive processes that lead to loss of the insulin-producing β cells of the 
pancreas are largely mediated by CD4+ and CD8+ classes of T cells that are activated by 
antigen presenting cells (APCs) such as DCs and macrophages. APCs have been shown 
to present β cell antigens to the effector T cells to stimulate an autoimmune response 
(Morran et al., 2008; Wang et al., 2016). 
Dendritic cells are the principal APCs of the human immune system and are 
crucial for priming T cells during the immune response. These cells also prevent 
autoimmunity by maintaining central and peripheral tolerance under steady-state 
conditions (Benson et al., 2014; Ohnmacht et al., 2009). DCs are a heterogeneous group 
of antigen presenting cells and are widely distributed within body tissues, mediating and 
shaping immune signals between innate immunity and the adaptive immune response, 
thereby playing a central role in the break-down of self-tolerance during the pathogenesis 
of autoimmune diseases (Benson et al., 2014).  
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Strategies for Therapy 
Numerous biologic therapeutic options have been approved for many autoimmune 
diseases such as psoriasis and multiple sclerosis. However, the limiting factors of cost 
and determination of the therapeutic choice best suited for individual patients continue to 
persist (Steinman et al., 2012). Despite the progress in the development of therapy for 
autoimmune conditions, it is known now that one therapeutic strategy may not be 
applicable for treatment across all autoimmune disease spectrum, as the underlying 
biological mechanism for each autoimmune disease differs(Steinman et al., 2012). For 
example, although TNF-α has been implicated in the pathology of multiple sclerosis 
(MS) and therapeutic strategy involving the blockade of TNF has been developed, its role 
in the regeneration and proliferation of oligodendrocytes has been established thereby 
confounding the benefits of any therapy for MS that is based on antagonizing TNF-α 
(Arnett et al., 2001; Group and Group, 1999). An understanding of the basic mechanism 
of the autoimmune disease is therefore imperative for the development of effective 
therapeutic strategies. 
Even with these apparent successes of therapy, there are still some autoimmune 
conditions that lack approved therapies such as type 1 diabetes (T1D) and myasthenia 
gravis (Steinman et al., 2012). Available treatments are broad sweeping, targeting normal 
immune cells as well as the pathogenic cells; therefore re-directing the antigen-specificity 
of the autoreactive immune cells present in these conditions towards self- tolerance, may 
be key to therapeutic management of these autoimmune conditions (Peakman and von 
Herrath, 2010; Steinman et al., 2012). 
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Current strategies for the treatment of autoimmune diseases include biologic and 
non-biologic agents that modulate the immune response by interacting with either 
specific effector cells, secreted pro-inflammatory factors or molecular pathways 
(Coutinho and Chapman, 2011; Her and Kavanaugh, 2016; Kivity et al., 2010; Lewis and 
Allen, 2016; Rosman et al., 2013; Sharma and Scott, 2015)(Table 1.1).   
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Table 1.1  Approved therapies for autoimmune diseases. 
Category Agents Mechanisms 
Biologic Golimumab, Adalimumab, 
Infliximab (chimeric) 
Monoclonal antibodies 
directed against TNF-α. 
Etanercept TNF receptor IgG Fc fusion 
protein that binds to TNF. 
Sifalimumab A monoclonal antibody acting 
on IFN-α. 
Tociluzumab Anti-IL-6- receptor 
monoclonal antibody. 
Secukinumab A monoclonal antibody 
directed against IL-17A. 
Anakinra, Canakinumab Blocks IL-1 
Rituximab (chimeric), 
Ofatumumab 
Monoclonal antibodies 
directed against CD20 protein 
expressed on B cells. 
Epratuzumab Anti-CD22 monoclonal 
antibody acting on CD22 
molecule expressed on B cells. 
Intravenous immunoglobulins 
(IVIg) 
Diverse mechanisms are 
proposed; IVIg are purified 
immunoglobulin gamma 
obtained from plasma, pooled 
from thousands of healthy 
donors. 
Abatacept A CTLA-4: IgG Fc fusion 
protein which binds to 
costimulatory molecules on 
antigen presenting cells 
(APC), CD80/CD86, to inhibit 
CD28 activation on T cells. 
Non-biologic Methotrexate Exact mechanism unclear; A 
folate analogue, it probably 
inhibits actively dividing cells 
by blocking folate-dependent 
enzymes. 
Glucocorticoids (GC) Immunosuppressive; Binds to 
GC receptors to inhibit NFκB 
signaling. 
Mycophenolate mofetil An antibiotic derived from 
Penicillium sp. that targets 
GMP synthesis to inhibit T 
and B cell proliferation and 
cytokine expression of 
immune cells. 
Abbreviations: TNF, Tumor Necrosis Factor; IL, interleukin; IFN, interferon. 
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With advancements in medical science and biotechnology, immunotherapy (the 
use of immunological materials for treatment purposes (Feldmann and Steinman, 2005)) 
is not restricted to the biologic agents listed in Table 1.1, and these biologic agents may 
also result in general immunosuppression. Other forms of immunotherapy have been 
developed to mitigate the condition of autoimmunity; these include the application of 
immune cells and vaccines (Feldmann and Steinman, 2005). Cell-based therapy which 
includes adoptive transfer of regulatory T cells (Tregs), proffers an antigen-specific 
strategy to inhibit the activity and proliferation of auto-inflammatory immune cells 
(Arellano et al., 2016). Therapies applying the regulating potential of T cells are more 
advantageous than nonspecific immune regulating strategies, since nonspecific 
approaches may result in generalized blocking of the immune response, initiating 
immune-compromise and susceptibility of the immune system to infections (Arellano et 
al., 2016). Preclinical animal studies and a Phase I clinical trial have demonstrated the 
prevention of autoimmune diseases by adoptive transfer of regulatory T cells (Marek-
Trzonkowska et al., 2014; Roncarolo and Battaglia, 2007).    
Stem cells are another group of cell-based therapy currently under investigation 
and development for the treatment of autoimmune conditions. Mesenchymal stem cells 
(MSC) possess immune regulating properties (Munir and McGettrick, 2015) that can be 
harnessed for autoimmune disease therapy and induced pluripotent stem cells (iPSCs) can 
be developed into antigen-specific Tregs for adoptive transfer therapy in autoimmune 
disease conditions(Haque et al., 2016). 
The use of vaccines to induce “inverse vaccination” is currently under 
development. Inverse vaccination implies the antigenic stimulation of the immune 
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response towards specific inhibition or elimination of specific antibody and T cell 
immunological responses (Steinman, 2010). The aim of inverse vaccination is to 
specifically tolerize the pathological response of the adaptive immune system of the 
autoimmune diseases (Steinman, 2010). For example, DNA vaccination strategy 
delivering plasmids encoding self-antigens to immune cells, have demonstrated efficacy 
in preventing and reversing autoimmune conditions in experimental autoimmune 
encephalomyelitis EAE mouse models (Garren et al., 2001; Ho et al., 2005). Human trials 
of DNA vaccines have been initiated for multiple sclerosis (MS) and efforts to develop 
such DNA vaccines for T1D are in progress (Garren et al., 2008; Steinman, 2010). Other 
vaccine strategies for the induction of tolerance involve the use fusion proteins consisting 
of epitopes of self-antigens and cytokines (Mannie et al., 2012; Mannie et al., 2007), or 
self-antigens and immunogenic subunits (Carter et al., 2006b; Sadeghi et al., 2002).  
Most of these vaccine strategies target the feature of antigen presenting cells 
(APC) especially DCs, in processing and presenting antigens, to deliver the potency of 
the vaccine in inducing tolerance. With the growing necessity for treatment options for 
autoimmune diseases that are potent and safe, DC-based vaccines are arising as potential 
tools for therapy of autoimmune diseases. This form of cell-based therapy combines the 
principles of inverse vaccination with adoptive transfer of antigen-specific 
immunological materials, which in this case are DCs, for the induction and restoration of 
immune regulation (Sabado et al., 2017; Ten Brinke et al., 2015). In the following sub-
section, a brief discussion of an immunosuppressive vaccine strategy is provided. 
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The Immunosuppressive Fusion Protein Vaccine CTB-PROINSULIN (CTB-INS) 
Cholera toxin B subunit-proinsulin fusion protein (CTB-INS) is a chimeric fusion 
protein vaccine comprised of the cholera toxin B subunit conjugated to the diabetes 
autoantigen, proinsulin. The chimeric protein is translated from a fusion gene encoding 
the cholera toxin B sub-unit linked by a c-terminal fusion to proinsulin, in the 
Escherichia coli expression vector, pRSET A (Carter et al., 2006a; Odumosu et al., 2010) 
(Fig. 1.1). The rationale for applying CTB-INS as strategy for the therapy of autoimmune 
diabetes, emanates from the observation that administration of autoantigens reduce the 
development of autoimmune conditions in several studies and the induced tolerance 
could be prolonged, sustained and amplified by utilizing the potential of CTB as an 
efficient trans-mucosal carrier delivery molecule (Sadeghi et al., 2002; Sun et al., 1994; 
Zhang et al., 1991) to increase the efficiency of delivery and enhance presentation of the 
autoantigen to effector T cells (Sadeghi et al., 2002). Murine studies have shown that oral 
and peritoneal delivery of a conjugate of the non-toxic B subunit of the cholera toxin 
(CTB) to specific autoantigens, was able to induce tolerance, in several autoimmune 
conditions in mice, such as uveitis, autoimmune encephalomyelitis and autoimmune 
chondritis (Kim et al., 2001; Phipps et al., 2003; Sun et al., 2000). Specific linkage of the 
CTB subunit to the diabetes autoantigen, insulin, has been shown to suppress 
development of autoimmune diabetes in the non-obese diabetic (NOD) mice (Arakawa et 
al., 1998; Aspord and Thivolet, 2002; Dénes et al., 2006). Recent experiments in our 
laboratory have revealed the vaccine can suppress pro-inflammatory activation of human 
dendritic cells (Odumosu et al., 2011b), induce upregulation of IDO biosynthesis 
(Mbongue et al., 2015), and upregulate expression of immunoregulatory proteins and 
 9 
cytokines, such as integrins and TGF-β1 (Chapter 3). The mechanisms of CTB-INS 
immuno-modulatory effects in human moDCs is under investigation (Chapter 2; Chapter 
3) and is essential for evaluation of vaccine efficacy and safety as a therapeutic agent for 
T1D. 
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Figure 1.1: Plasmid map of the E. coli expression vector, pRSET A (Invitrogen, Carlsbad, 
CA), carrying the CTB-INS fusion gene. The expression vector is under the control of the 
bacteriophage T7 promoter and contains an oligonucleotide region that encodes 6 histidine 
amino acid residues immediately 5’ upstream of the CTB gene sequence. 
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Dendritic Cells and Their Role in the Induction of Immune Tolerance 
Dendritic cells (DC) are a heterogeneous population of APCs that develop from 
bone marrow precursors that migrate to the lymphoid and non-lymphoid tissues (NLT) 
for further differentiation (Boltjes and van Wijk, 2014). Three circulating DC subsets, in 
peripheral human blood have been described: The CD11c+ myeloid/conventional DCs 
expressing the CD1c+ surface marker, the CD11c+ myeloid/conventional DCs  expressing 
CD141+, and CD123+ BDCA-2+ plasmacytoid DCs (Boltjes and van Wijk, 2014). 
Plasmacytoid DCs circulate in the blood and lymphoid tissues and produce copious 
amount of Type 1 interferons (IFN) in response to viral pathogens. These cells appear 
tolerogenic when inactive, but attain immunogenic phenotypic expression upon activation 
(Boltjes and van Wijk, 2014; Mathan et al., 2013). Conventional DCs are found in the 
blood, lymph node (LN), spleen, and NLT. Both CD11c+ myeloid/conventional DC types 
show differences in cytokine/chemokine repertoire and TLR patterns during an 
immunological response (Boltjes and van Wijk, 2014). A distinct population of DCs has 
also been recently identified to be associated with inflammatory cellular environments 
and appear to be the in vivo equivalents of in vitro monocyte-derived dendritic cells 
(moDCs) as confirmed by transcriptome analyses (Segura et al., 2013). The discovery of 
the potential for human peripheral blood monocytes to differentiate into DCs is a 
valuable tool and has enabled research in DC biology and development of DC therapeutic 
applications which were otherwise a challenge due to the low level of circulating DCs 
(León et al., 2005; Sallusto and Lanzavecchia, 1994). 
DCs are the most potent antigen presenting cells and are crucial in initiating and 
modulating adaptive immune cells. The flexibility of DCs’ features and function in 
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response to cellular environmental cues, enables them to direct the outcome of the 
adaptive immune response (van Duivenvoorde et al., 2006). As sentinels of the immune 
system DCs constantly patrol for danger signals of antigens from pathogens, self-tissues, 
and cancerous cells called pathogen-associated molecular patterns (PAMP) or damage-
associated molecular patterns (DAMP) that are detected using pattern recognition 
receptors (PRR) such as Toll-like receptors (TLR) and C-type lectin receptors (CLRs) 
expressed on the DC cell surface (Schinnerling et al., 2015; Van Brussel et al., 2014). 
Recognition of any of these ‘red flag’ molecular signatures activates and induces a DC 
differentiation process that involves DC maturation and homing to T lymphocyte zones  
(Randolph et al., 2008).  Activating signals may arise from direct DC contact with 
antigens, by indirect stimulation via nonspecific tissue response induced by the pathogen 
or by cytokine expression from the cellular environment (Kaliński et al., 1999; 
Schinnerling et al., 2015). Upon DC uptake of the antigens, simultaneous processing, 
presentation of the peptide antigen on major histocompatibility molecules (MHC), and 
upregulation of costimulatory molecules (CD80 and CD86) follows and DCs migrate to 
the lymph nodes. DC engagement of peptide-MHC complex with T cell receptor (TCR) 
followed by delivery of costimulatory molecule signals, and DC priming of T cells with 
specific cytokine profile, initiates naïve T cell activation and polarization to antigen 
specific T helper type 1 (Th1) or Th2, or stimulation of effector and memory T cell, 
depending on the signal delivered (García-González et al., 2016; Kaliński et al., 1999; 
Randolph et al., 2008; Schinnerling et al., 2015). 
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Tolerogenic Dendritic Cells 
Tolerogenic DCs are generally characterized by an immature or semi-immature 
phenotype demonstrated by expression of low costimulatory molecules, high expression 
of anti-inflammatory cytokines, decreased expression of pro-inflammatory cytokines, and 
induction of hyporesponsive CD4+ T cells (Hilkens et al., 2010; Schinnerling et al., 
2015; Ten Brinke et al., 2015).  Tolerogenic DCs can be generated in vitro for further use 
as cellular vaccines, by genetically engineering DC expression of immunoregulatory 
factors, and by applying pharmacological agents such as dexamethasone, vitamin D3, and 
rapamycin to DCs. Otherwise, conditioning of DCs with anti-inflammatory cytokines 
such as IL-10 and TGF-β may biologically mediate the induction of tolerogenic DCs 
(Hilkens et al., 2010).  DCs may also be targeted in vivo by utilizing an auto-antigen 
delivery system that specifically primes the DCs to induce tolerance of adaptive immune 
cells involved in an autoimmune response (Hilkens et al., 2010; Mukhopadhaya et al., 
2008). Tolerogenic DCs mediate tolerance by inducing anergy (inactivation of T cells), 
or, apoptosis of antigen specific autoreactive T cells (Mahnke et al., 2002), and skew 
effector T cell immune response into the anti-inflammatory Th2-like phenotype or induce 
the generation of Treg cells (Van Brussel et al., 2014; van Duivenvoorde et al., 2006). 
Successful experimentation in various animal models have led to application of 
tolerogenic DC therapy in several clinical trials (Benham et al., 2015; Giannoukakis et 
al., 2011; Jauregui-Amezaga et al., 2015). 
Although a specific and unique molecular biomarker has not been identified to 
indicate DC tolerogenicity, several molecules and pathways have been shown to be 
involved with DC modulatory properties (Schinnerling et al., 2015). These include (1) 
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signaling enzymes, (2) transcription factors and adapter molecules, (3) DC membrane 
inhibitory receptors as described below. 
 
Signaling Enzymes  
Heme oxygenase-1 (HO-1) regulates DC activation, induces antigen specific 
Tregs in a murine model (Wong et al., 2016), inhibits the expression of proinflammatory 
cytokines, and is mainly expressed by immature DCs (Blancou et al., 2011; Schinnerling 
et al., 2015). Extracellular signal-regulated kinases (ERK) activation in DCs induces 
expansion of Treg population and generation of regulatory DCs (Arce et al., 2011; 
Schinnerling et al., 2015). DCs upregulate ectonucleoside triphosphate 
diphosphohydrolase-1 (ENTPD1), also known as CD39, in response to IL-27 signaling, 
for the induction of Treg cells and to suppress the progression of experimental 
autoimmune encephalomyelitis (EAE), the mice model of MS (Mascanfroni et al., 2013). 
ENTPD1 is a cell surface enzyme predominantly expressed by conventional DCs (cDCs) 
that limits levels of extracellular ATP (Mascanfroni et al., 2013). ENTPD1 deficiency 
resulted in increased IL-1β release and DCs conditioned with IL-27 utilized ENTPD1 to 
suppress the differentiation of pathogenic effector  T cells (Mascanfroni et al., 2013). 
 
Transcription Factors and Adaptor Molecules 
The nuclear factor-κB1 (NF-κB1) p50 homodimer promotes the anti-
inflammatory response of DC by acting as a transcriptional repressor of DC activation, 
and regulating DC expression of effector T cell activating factors (Dissanayake et al., 
2011; Schinnerling et al., 2015). Others include, Peroxisome-proliferator activated 
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receptor (PPAR)-γ which is highly expressed on immature human monocyte-derived DCs 
(Gosset et al., 2001) and has been shown to reduce the capacity for T cells to induce 
lymphocyte proliferation in these cells (Nencioni et al., 2002). Suppressor of cytokine 
signaling (SOCS) proteins, a group which has numerous immunoregulatory functions 
including the modulation DC phenotype into a tolerogenic profile and the suppression of 
DC activation (Hanada et al., 2003; Li et al., 2006c). The duo of aryl hydrocarbon 
receptor (Ahr) and indoleamine 2,3-dioxygenase (IDO), an enzyme that catabolizes 
tryptophan into immunosuppressive metabolites such as kynurenines, modulates DC 
mediated induction of Tregs and inhibition of T cell proliferation (Nguyen et al., 2010). 
 
Dendritic Cell Membrane Inhibitory Receptors 
Surface molecules such as Fc gamma receptor IIB (FcγRIIB), expressed on DCs, 
modulates peripheral tolerance by suppressing DC costimulatory molecule expression 
and directing T cell differentiation to a tolerogenic phenotype (Samsom et al., 2005). 
Also, overexpression of FcγRIIB enables immature DCs to resist toll-like receptor (TLR) 
induced maturation signals (Zhang et al., 2011). Cell membrane Ig-like transcripts (ILTs) 
are represented by members such as ILT3 and ILT4 that transmit suppressive signals via 
cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM), resulting in 
increase of circulating Treg cells  (Cella et al., 1997; Stallone et al.). Targeting 
autoantigens to DEC-205, a dendritic cell C-type lectin receptor (CLR), has been 
demonstrated to induce the conversion of autoreactive effector T cells to Foxp3(+) Treg 
cells (Petzold et al., 2010). 
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Further research to elucidate the key regulators of DC tolerogenicity remain 
highly imperative so as to monitor the induction and therapeutic efficacy of tolerogenic 
DCs (Schinnerling et al., 2015). In the following section, specific immunomodulatory 
factors implicated in CTB-INS-mediated immune tolerance of human moDCs are further 
discussed. 
 
Potential Molecules and Pathways Involved in CTB-INS Immunomodulation of DCs 
Indoleamine 2, 3- dioxygenase (IDO) 
Indoleamine 2, 3- dioxygenase is an enzyme that catalyzes the breakdown of 
tryptophan, an essential amino acid, to degradation products called kynurenines. The 
activity of the enzyme has been shown to impact immune suppression and peripheral 
tolerance (Fallarino et al., 2012; Harden and Egilmez, 2012). Immune cells express IDO 
for immune regulation. Recently, B cells have been shown to induce regulatory T-cells 
by a TGF-β/IDO axis requiring the production of TGF-β1 and IDO upon stimulation of 
the B cells (Nouël et al., 2015). A combined inhibition of TGF-β1 and IDO resulted in 
the loss of B cell regulatory capacity (Nouël et al., 2015). Dendritic cells expressing IDO 
generate regulatory T cells in an arthritis mouse model (Park et al., 2008). The role of 
IDO in conferring tolerance to immune cells, specifically dendritic cells, has also been 
highlighted in other experimental models of autoimmune diseases such as autoimmune 
haemolytic anaemia, asthma, and autoimmune diabetes (Dahal et al., 2013; Grohmann et 
al., 2003; Hayashi et al., 2004). These studies indicate that IDO may be a marker for 
tolerogenicity. Further, recent studies in our lab show that CTB-INS induces IDO 
biosynthesis in human moDCs (Mbongue et al., 2015). 
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Integrin alpha v beta 8 (αvβ8) 
Integrins are heterodimeric glycoprotein molecules that function as cell adhesion 
receptors to modulate the cellular response to the extracellular environment by interacting 
with ligands, cytoskeletal and cytoplasmic-signaling molecules (Nishimura et al., 1994).  
These molecules consist of an α and a β subunit, each with a large extracellular domain, a 
transmembrane and a cytoplasmic domain (Evans et al., 2009; Nishimura et al., 1994). 
Members of the integrin αv family, which include αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, are able 
to bind to a tri-amino acid motif, Arg-Gly-Asp (RGD), present on the latency associated 
peptide (LAP) region of the latent TGF-β1 protein complex, and some αv integrins can 
further activate latent TGF-β1, following binding to the RGD sequence. Knock-in mice 
with a point mutation in the TGF-β1 integrin binding site exhibit a phenotype similar to 
TGF-β1 null mice and die from multi-organ inflammatory disease early in their 
development indicating the relevance of the integrin binding site to normal functioning of 
TGF-beta (Worthington et al., 2012; Yang et al., 2007). All αv or RGD-binding integrins 
have been implicated in the activation of TGF-β1 (Henderson et al., 2013; Hinz, 2013; 
Leask and Hutchenreuther, 2014; Reed et al., 2015; Song et al., 2016; Wipff and Hinz, 
2008). Integrin αvβ8 has been well characterized to be critical for TGF-β1 activation and 
in maintaining immune homeostasis.  Mice whose leucocytes are deficient in integrin 
αvβ8 develop a wasting inflammatory disorder (Aluwihare et al., 2009b; Mu et al., 2002; 
Travis et al., 2007b). This abnormality is matched by mice specifically lacking the 
expression of integrin αvβ8 integrin on DCs and the integrin-deficient DCs fail to induce 
regulatory T cell differentiation in vitro (Aluwihare et al., 2009b; Travis et al., 2007a). 
Alpha (v) integrins are also considered as apoptotic cell receptors associated with 
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clearance of apoptotic cells; These molecules appear to enable apoptotic cell recognition 
for TGF-β activation and the initiation of immunosuppressive signaling (Païdassi et al., 
2010). In murine immune cells, expression of integrin αvβ8 is mostly restricted to CD4+T 
cells and DCs (Travis et al., 2007b; Travis and Sheppard, 2014). Also, integrin αvβ8 
appears to be the only αv integrin these cells express (Edwards et al., 2014; Travis et al., 
2007a; Worthington et al., 2012). Integrin αvβ8 is highly expressed in intestinal DC 
subsets of mice and is required for generation and function of regulatory T cells. 
(Païdassi et al., 2011; Worthington et al., 2012; Worthington et al., 2015). Recent 
investigations in our laboratory reveal that CTB-INS induces upregulation of integrin 
αvβ8 expression in human moDCs (Chapter 3). 
 
Transforming Growth Factor Beta (TGF-β) 
The pleiotropic cytokine TGF-β belongs to the TGF-β superfamily of growth 
factors and functions in numerous physiological and pathological processes including the 
immune response. The cytokine plays a central role in T cell development, homeostasis, 
tolerance and differentiation (Guerder et al., 2013). While TGFβ exists in three isoforms 
in mammals as TGF-β1, TGF-β2 and TGF-β3 (Mu et al., 2002), TGF-β1 is the most 
expressed isoform in immune cells (Li et al., 2006a; Melton et al., 2010). TGF-β1 is 
critical for the regulation of DC immune responses and in the maintenance of immune 
cell homeostasis (Worthington et al., 2012). Increase in TGF-β1 production has been 
shown to be associated with immune defense and/or recovery from autoimmune diseases 
(Li et al., 2006b; Prud'homme and Piccirillo, 2000). In mice, gene deletion of TGF-β1 or 
TGF-β1 signaling proteins results in multifocal autoimmune disorders and inflammatory 
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states that mimick several autoimmune diseases (Aoki et al., 2005; Kriegel et al., 2006; 
Prud'homme and Piccirillo, 2000). Studies have shown that TGF-β1 induced IDO 
expression and signaling in murine plasmacytoid DCs (pDCs) and splenic DCs in a 
manner that resulted in sustained tolerance in the DCs (Belladonna et al., 2008; Pallotta et 
al., 2011). However, our studies reveal that TGF-β1 may not induce IDO expression in 
human moDCs, but may be involved in CTB-INS tolerance induction of human moDCs 
by alternative mechanisms that require further clarification (Chapter 3). 
TGF-β1 is synthesized and expressed as a latent form that requires activation to 
exert its biological functions. After furin cleavage in the Golgi, the inactive complex 
consists of an N-terminal portion that is a disulfide-linked homodimer called the latency 
associated peptide (LAP), and a C-terminal fragment that is also a disulfide-linked 
homodimer of the mature cytokine. Both peptides are non-covalently associated and form 
the small latent complex (SLC) also called latent TGF-β1. The crystal structure of the 
SLC has revealed that the LAP encircles the active TGF-β1 fragment thereby prohibiting 
its contact sites from interacting with TGF-β receptors and thus prevents induction of a 
signaling response (Li et al., 2006b; Travis and Sheppard, 2014). TGF-β1 activation can 
be mediated by extreme pH and heat, thrombospondins, proteases and integrins (Li and 
Flavell, 2008; Li et al., 2006b). The active cytokine signals by binding to the TGF-β 
receptor type II dimer (TGFβRII) that associates with the TGF-β receptor type I dimer 
(TGFβRI) to form a tetrameric receptor complex, inducing phosphorylation of the 
cytoplasmic domain of TGFβRI, and subsequent phosphorylation of the intracellular 
signal transducers, Smad2 and Smad3. Upon activation, the Smad2/3 proteins bind to 
Smad4 to form a complex and translocate to the nucleus where the complex initiates 
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transcription of target genes (Massagué, 2012; Travis and Sheppard, 2014; Wipff and 
Hinz, 2008). TGF-β1 also signals through Smad-independent routes and the mechanisms 
for these pathways remain to be fully elucidated (Li et al., 2006b; Travis and Sheppard, 
2014). Our studies show that CTB-INS stimulates TGF-β1 expression and Smad2/3 
signaling in human moDCs (Chapter 3).   
 
Summary and Conclusion 
The need to develop effective therapy for autoimmune conditions that is antigen-
specific, efficient and safe remains paramount, and DCs are promising tools for therapy 
based on their unique functions in the immune system. CTB-INS has proven to be an 
effective agent for inducing tolerance in human DCs and may hold promise for 
application as a therapeutic tool in the treatment of type 1 diabetes. However, the 
mechanism of action of CTB-INS requires further validation. 
In this dissertation, we document our findings on the mechanism of CTB-INS 
induction of tolerance in human DCs. Data presented here reflect our efforts to test the 
hypotheses presented in Fig. 1.2. We also attempt to provide clarification on the 
relationship between the immunosuppressive cytokine TGF-β1 and immunomodulatory 
enzyme, IDO, as studied in human moDCs. We anticipate that these novel findings will 
improve the understanding of human moDC biology and the mechanisms and molecular 
interactions that occur when human moDCs acquire tolerogenicity.  
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Figure 1.2. Schematic of the hypotheses tested in this dissertation. Hypothesis 1: CTB-
INS stimulates biosynthesis of TGF-β superfamily members in human moDCs for the 
induction of intracellular signaling of gene activation that leads to IDO1 transcription and 
protein synthesis; 2: CTB-INS induces integrin αvβ8 production to mediate TGF-β1 
activation for  tolerogenic functions such as induction of IDO1 biosynthesis. a-TGF-β, 
active TGF-β; L- TGF-β, Latent TGF-β. 
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Abstract 
A chimeric protein vaccine composed of the cholera toxin B subunit fused to 
proinsulin (CTB-INS) was shown to suppress type 1 diabetes onset in NOD mice and 
upregulate biosynthesis of the tryptophan catabolic enzyme indoleamine 2, 3-
dioxygenase (IDO1) in human dendritic cells (DCs). Here we demonstrate siRNA 
inhibition of the NF-κB-inducing kinase (NIK) suppresses vaccine-induced IDO1 
biosynthesis as well as IKKα phosphorylation. Chromatin immunoprecipitation (ChIP) 
analysis of CTB-INS–inoculated DCs showed that RelB bound to NF-κB consensus 
sequences in the IDO1 promoter, suggesting vaccine stimulation of the non-canonical 
NF-κB pathway activates IDO1 expression in vivo. The addition of Tumor Necrosis 
Factor Associated Factors (TRAF) TRAF 2, 3 and TRAF6 blocking peptides to vaccine 
inoculated DCs was shown to inhibit IDO1 biosynthesis. This experimental outcome 
suggests vaccine activation of the TNFR super-family receptor pathway leads to 
upregulation of IDO1 biosynthesis in CTB-INS inoculated dendritic cells. Together, our 
experimental data suggest the CTB-INS vaccine uses a TNFR-dependent signaling 
pathway of the non-canonical NF-κB signaling pathway resulting in suppression of 
dendritic cell mediated type 1 diabetes autoimmunity. 
 
Introduction 
Type 1 diabetes (T1D) is a well-studied prototypic tissue specific autoimmune 
disease resulting from auto-reactive lymphocyte destruction of the pancreatic islet 
insulin-producing β-cells (Eisenbarth, 1986; Tisch & McDevitt, 1996). The progressive 
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loss of islet β-cell function leads to insulin deficiency and high blood glucose levels 
(hyperglycemia). Increased levels of cellular oxidative stress and chronic inflammation 
generated by hyperglycemia leads to neural and circulatory complications that result in an 
early mortality from amputation, loss of kidney function, blindness, heart attack, and 
stroke (Forbes & Cooper, 2013; Melendez-Ramirez, Richards, & Cefalu, 2010). 
Due to the high cost and extended duration of palliative patient care, there is an 
urgent need for therapeutics that can safely deliver specific effective therapy that protects 
against the onset and reverses the progression of tissue specific autoimmunity. Dendritic 
cells, which are considered the most prominent subset of professional antigen presenting 
cells (APC), have been implicated in the initiation of diabetes-related islet β-cell 
destruction (Allen et al., 2009; Ganguly, Haak, Sisirak, & Reizis, 2013; J. Mbongue, 
Nicholas, Firek, & Langridge, 2014). Effective immunological suppression strategies 
include chimeric vaccines that link immuno-stimulatory molecules (adjuvants) with 
autoantigens to enhance vaccine efficacy (Aspord & Thivolet, 2002; Bergerot et al., 
1997; Ploix et al., 1999). Prominent among the adjuvants used is the cholera toxin B 
subunit (CTB) (Odumosu, Nicholas, Yano, & Langridge, 2010). C-terminal linkage of 
CTB to the diabetes autoantigen proinsulin (CTB-INS), generated a fusion protein shown 
to protect against T1D onset (Ploix et al., 1999). Oral immunization experiments showed 
that feeding small amounts (2–20μg) of CTB-INS vaccine protein alone or in 
recombinant plant tissues effectively suppressed β-cell destruction and clinical diabetes in 
adult non-obese diabetic (NOD) mice (Aspord & Thivolet, 2002; Bergerot et al., 1997; 
Denes et al., 2005). 
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Proteomic analysis of human dendritic cells inoculated with CTB-INS revealed 
strong up-regulation of the tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase 
(IDO1) (J. C. Mbongue et al., 2015). Previous observations showed that CD40 ligand 
(CD40L) induced IDO1 biosynthesis in human DCs through activation of the non-
canonical NF-κB signaling pathway (Tas et al., 2007). Thus, we assessed the requirement 
for NF-κB activation in vaccine up-regulation of IDO1 using ACHP and DHMEQ, 
pharmacological inhibitors of NF-κB (J. C. Mbongue et al., 2015). While these 
experiments revealed vaccine stimulation of NF-κB was essential to activate IDO1 
biosynthesis, the relative contributions of canonical and non-canonical NF-κB pathways 
required for CTB-INS induction of IDO1 biosynthesis remained undetermined. 
The NF-κB family in mammals is composed of five members, including c-Rel, 
RelA also known as p65, NF-κB1 known as p50, RelB, and NF-κB2 known as p52. 
These NF-κB family members form a variety of dimeric complexes capable of 
transactivating numerous target genes through binding to the κB enhancer (Sun, 2011). 
The NF-κB subunit proteins are normally found inactive in the cell cytoplasm due to 
binding by a family of inhibitors that include IκBa and several additional related ankyrin 
repeat containing proteins (Sun, 2011; Sun & Ley, 2008). 
Due to the diversity of NF-κB functions, its activity is under tight control at 
multiple levels by positive and negative regulatory elements. Under resting conditions, 
NF-κB dimers are bound to inhibitory IκB proteins that retain NF-κB complexes in the 
cytoplasm. In the canonical signaling pathway, the degradation of IκB inhibitor proteins 
is initiated through stimulus-induced phosphorylation by IκB kinase (IKK), a molecular 
complex consisting of two catalytically active kinases, IKKα and IKKβ, and their 
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regulatory subunit IKKγ (NEMO). Phosphorylation of IκB proteins target them for 
ubiquitination and proteasome degradation, releasing the NF-κB RelA (p65) and p50 
protein dimers for translocation into the nucleus. 
The non-canonical NF-κB signaling pathway was discovered during analysis of 
non-canonical p100 subunit processing (Sun, 2011; Xiao, Fong, & Sun, 2004). In 
addition to serving as a precursor of the functional p52 subunit, p100 was shown to 
function like an IκB inhibitor molecule, preferentially inhibiting RelB nuclear 
translocation (Solan, Miyoshi, Carmona, Bren, & Paya, 2002; Sun, 2011). Partial 
proteasome processing of p100 serves to generate p52 and to induce nuclear translocation 
of the RelB/p52 heterodimer, as RelB binds to DNA with p52. The p52 subunit is 
actively generated predominantly in specific immune cell types including B-cells and 
dendritic cells, leading to the idea that p100 processing might be a signal-regulated event. 
Indeed, the NF-κB-inducing kinase (NIK) is required for p100 processing and is required 
for in vivo p100 processing in splenocytes (Xiao et al., 2004; Xiao, Harhaj, & Sun, 2001). 
The first component of the non-canonical signaling pathway to be identified was NIK, a 
MAP-kinase kinase kinase (MAP3K) member originally implicated in NF-κB activation 
by the TNF receptor (TNFR) pathway (Malinin, Boldin, Kovalenko, & Wallach, 1997). 
To date, all of the non-canonical NF-κB inducers identified are known to signal through 
NIK (Coope et al., 2002; Manches, Fernandez, Plumas, Chaperot, & Bhardwaj, 2012; Tas 
et al., 2007). 
Here we focus on identification of non-canonical NF-κB signaling pathway 
contributions to CTB-INS vaccine induction of IDO1 in human dendritic cells as a 
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prerequisite for application of chimeric vaccine immune suppression strategies in the 
clinic. 
 
Materials and Methods 
Construction of a Bacterial Expression Vector Containing the Cholera Toxin B 
Subunit – Proinsulin Gene 
A DNA sequence encoding 258bp of the human proinsulin gene (INS M12913.1) 
was linked to the carboxyl-terminus of a DNA fragment (309bp) encoding the cholera 
toxin B subunit gene (CTB U25679.1) to generate the fusion gene CTB-INS according to 
a previously used protocol (J. C. Mbongue et al., 2015) (Figure 2.1). 
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Figure 2.1. CTB-INS fusion protein was expressed from the E.coli pRSET A expression 
vector and purified using Ni-NTA agarose with the indicated imidazole concentration in 
the wash and elution steps. Panel (A) is a plasmid map of the E. coli expression vector 
pRSET A (Invitrogen, Carlsbad, CA), carrying the CTB-INS fusion gene. Panel (B) shows 
the SDS-PAGE. Proteins were visualized by Coomassie staining. Lane NI: non-induced E. 
coli (BL21) cell; I: induced E. coli cell; M: protein size marker; CL: cell lysate; FT: flow-
through; W: wash; E: elution. Panel (C) Western blot detection of recombinant CTB-INS 
fusion protein identified with anti-CTB primary antibody. The arrow indicates the purified 
CTB-INS proteins. Panel (D) shows the predicted CTB-INS protein structure using its 
protein sequence generated by the RaptorX server. 
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Expression and Purification of CTB-INS Fusion Protein in E. coli 
The E. coli strain BL21 was transformed with pRSET-CTB-INS as previously 
described (J. C. Mbongue et al., 2015). 
 
Ethics 
Ex vivo experiments on monocyte-derived DCs were performed, with aphaeresis 
blood provided by the Life Stream Blood Bank (San Bernardino, CA). These experiments 
were approved by the Loma Linda University Adventist Health Sciences Center 
Institutional Review Board and blood donor written consent. Blood donor information 
was anonymized and de-identified prior to the study. 
 
Isolation and Culture of Monocyte - derived Dendritic Cells from Human Peripheral 
Blood 
Monocyte-derived dendritic cells (MoDCs) were prepared from freshly collected 
human peripheral blood cells isolated from aphaeresis filter cones obtained from the 
LifeStream blood bank (San Bernardino, CA). The blood was incubated with a red blood 
cell lysis buffer (3.0 mL Lysis Buffer/ mL of blood) containing 8.3g/L NH4Cl, 1g/L 
KHCO3, and 1.8 mL 5% EDTA (Boston Bioproducts), and centrifuged for 5 minutes at 
1,500 rpm at 4°C in a Beckman Coulter Allegra X-15R centrifuge, equipped with a 
SX4750 rotor. After a total of 3 washes in PBS to remove cellular debris and hemoglobin 
CD14+ monocytes were obtained from the total lymphocyte fraction by incubation with 
anti-CD14 antibodies bound to magnetic beads for 15 minutes at 4°C (Miltenyi Biotech, 
Auburn, CA). The monocytes were separated from other immune cells by binding to a 
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magnetic MACS column followed by elution of all other leucocytes (Miltenyi Biotech, 
Auburn, CA). The monocytes were eluted from the column and cultured at a 
concentration of 2-9 x 106 cells/well in 6-well non-pyrogenic polystyrene culture plates in 
RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA), supplemented with 
10% FBS, 1mM glutamine, 100 U/ml penicillin, 100μg/ml streptomycin, 50ng/ml human 
recombinant GMCSF, and 10 ng/ml human recombinant IL-4 (ProSpec-Tany), at 37°C in 
a humidified atmosphere of 5% CO2 (Preprotech, Rocky Hill, NJ). The monocyte cell 
culture was fed at 2-day intervals by gentle replacement of 50% of the medium with fresh 
pre-warmed culture medium. The cells were cultured for a total of 6 days to allow 
monocyte differentiation into DCs prior to vaccine treatment. The cells were monitored 
by phase contrast microscopy to assess dendrite formation, a marker indicating DC 
differentiation. 
 
IDO1 Protein Synthesis in Vaccinated Dendritic Cells 
Approximately 2-9 x 106 monocyte-derived DCs generated from each of several 
subjects were inoculated with CTB-INS (0.1, 0.5, 1.0, 2.5, 5.0 and 10μg/ml), 500ng/ml of 
CD40L (Immunex, Seattle, WA), 500ng/ml of TRAF 2, 3 binding peptide (Proteintech 
Group, San Diego, CA) and 500 ng/ml of TRAF 6 binding peptide (Proteintech Group). 
The vaccinated DCs were incubated for 6, 12, 24, 48 or 96 hours and lysed in buffer C 
(20mM HEPES, 0.42 M KCl, 26% Glycerol, 0.1mM EDTA, 5mM MgCl2, 0.2% NP40, 
37ºC) containing a tablet of complete protease inhibitor (Roche, Basel, Switzerland) 
according to the manufacturer instructions. At least 50μg of protein isolated from the 
total DC lysate was separated by electrophoresis on a 12% polyacrylamide gel (SDS-
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PAGE). After transfer of the separated proteins to polyvinylidene difluoride (PVDF) 
membranes (Millipore, Temecula, CA), the presence of IDO1 protein (NP_002155.1) 
was detected by incubation of the blot for 12 hours at 4oC with an anti-IDO1 rabbit 
monoclonal primary antibody (Cat. 04-1056, clone EPR1230Y) (Millipore, Temecula, 
CA). For signal detection, the blot was washed 3 times with PBST (1X PBS, 0.02% 
tween 20, pH 7.4) and incubated for 2 hours at room temperature in the presence of a 
monoclonal anti-rabbit IgG γ-chain specific alkaline phosphatase conjugated secondary 
antibody (Cat. A-2556, clone RG-96) (Sigma-Aldrich). The immunoblots were washed 3 
times in PBST and incubated in 200μL of Novex® AP chemiluminescent substrate 
(Invitrogen™) for 5 minutes prior to exposure to x-ray film (Kodak X-Omat) for 3 
minutes. The IDO signal intensity was quantified via Image J software v. 1.48h. (Image J, 
NIH). 
 
Small Interfering RNA (siRNA) Transfection 
No pharmacological inhibitors for IKKα exist that selectively block the 
noncanonical pathway of NF-κB activation (Karin, Yamamoto, & Wang, 2004; Tas et al. 
2007). Here we used siRNA to specifically target this pathway. To define the regulatory 
effect of the NF-κB pathway on CTB-INS-induced IDO expression, human NIK-small 
interfering RNA (NIK siRNA, sc-36065) and non-targeting siRNA (Control siRNA 
Fluorescein conjugate, sc-36869) were purchased from Santa Cruz Biotechnology (Santa 
Cruz, Delaware, CA, USA). Monocytes were cultured in six-well plates for 4 days with 
50 ng/ml of hGM-CSF and 10 ng/ml of IL-4 to induce differentiation of DCs. siRNAs 
were transfected into DC cells using Lipofectamine® RNAiMAX reagent (Invitrogen, 
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Carlsbad, CA, USA) according to the manufacturer’s protocol. Three microliters of 
10μM siRNA was mixture in 150μl of Opti-MEM (Gibco-Life Technologies, Paisley, 
UK), while 9μl of Lipofectamine® RNAiMAX reagent was incubated in 150μl of Opti-
MEM at room temperature for 5 min. Then the diluted siRNA and Lipofectamine® 
RNAiMAX reagent were incubated for a further 20 min at room temperature for complex 
formation. The complexes were added to wells. The final siRNA concentration was 
25pmol. DC continued to be incubated at 37°C in 5% humidified CO2 for 48 h which 
was sufficient to significantly knock down the target protein levels. Expression of IDO1 
was induced by 5μg of CTB-INS for 24h after siRNA transfection. To evaluate 
transfection efficiency, FITC-labeled control RNA was substituted for siRNA. After 24 
hours, incubation, the transfected DCs were analyzed by fluorescence microscopy for 
intracellular FITC content. To confirm IKKα phosphorylation, DCs were treated with 
10μg/ml of CTB-INS for 6hrs after transfection and lysed in 100μL buffer C/well 
containing phosphatase inhibitors (50mM Sodium-beta-glycerophosphate, 1mM Sodium 
fluoride, 1mM Sodium-ortho-vanadate). Western blot analysis with Anti-IKK alpha 
(phospho S176+S180) (Abcam 1:1000) and anti-rabbit IgG whole molecule conjugated 
AP (Sigma-Aldrich 1:1000) was performed prior to band detection on x-ray film (Kodak 
XOmat) of IKKα.expression. 
 
Total RNA Preparation and Reverse Transcription Polymerase Chain Reaction  
(RT-PCR) 
Total RNA from 1 Х 106 DC was prepared using Trizol (Invitrogen, Carlsbad, 
CA, USA) and complementary DNA was synthesized from 2μg total RNA with oligo 
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(dT) primer in a 20μl reaction volume according to the manufacturer’s recommendations 
(Thermo Fisher Scientific Inc, Waltham, MA, USA). Polymerase chain reaction (PCR) 
amplification was performed at 95°C for 1m, 58 °C for 1m, 72°C for 30s, and PCR was 
done for 35 cycles. The primers used in this study were NIK (h)-PR (sc-36065-PR, Santa 
Cruze), product size 537bp; and β-actin forward, 5’-GCA TTG CTT TCG TGT AAA 
TTA TGT-3’ β-actin reverse, 5’-ACC AAA AGC CTT CAT ACA TCT CA-3’, product 
size 211bps. The PCR products were size-separated on 1.5% agarose gels and visualized 
by Et-Br DNA gel staining. 
 
ChIP Analysis of CTB-INS Induction of NF-κB Activation in Vivo 
A chromatin immunoprecipitation (ChIP) assay was performed to identify the 
specific binding sequences in the IDO1 promoter region for the non-canonical NF-κB 
subunits RelB protein using a MAGnifyTM Chromatin Immunoprecipitation System 
(Invitrogen) according to the manufacturer’s instructions. 3-8 x 106 Human dendritic cells 
were left unstimulated or were stimulated with CTB-INS for 3h, after which DC cells 
were harvested and washed with 1Х PBS and were fixed in formaldehyde (Sigma, St 
Louis, MO, USA) to a final concentration of 1%. After 10 min, 1.25M glycine was added 
to stop crosslinking reaction. After centrifugation, cells were lysed for 5 min in Lysis 
buffer supplemented with protease inhibitors. Chromatin was sheared by sonication (5 Х 
12s at one-fifth of the maximum potency) with a Sonic 60 Dismembrator (Fisher 
Scientific, Sunnyvale, CA, USA), centrifuged to pellet debris, and diluted in Dilution 
Buffer which was recommend in manufacturer’s instructions. Fragmented chromatin was 
immunoprecipitated with a ChIP-grade antibody against RelB (GeneTex, Irvine, CA, 
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USA) which was coupled with Dynabeads ®, at 4°C overnight. Immune complexes were 
washed with IP Buffer 1 and 2 in the DynaMagTM-PCR Magnet. For reversing the 
crosslinking, Reverse Crosslinking Buffer with proteinase K was added to both input 
control (fragmented chromatin without immunoprecipitation) and immune complexes and 
incubated at 55°C for 15 min. The DNA was purified with DNA Purification Magnetic 
Beads and buffers provided in the kit according to the manufacturer’s instructions. The 
immunoprecipitated DNA was used in each real-time PCR assay using primers specific 
for indicated regions of the DNA. The primers were designed using Primer Express 2.0 
software (PE Applied Biosystems, USA) under default parameters. The primers that were 
used are as follows: 5’-CGT TAA TGG TGA ATT CAG TGA TG-3’ (2732 F1) and: 5’-
TGC AGA GGG ACC TTC ATT CAA G-3’ (2732 R1), 5’-GGT AGA GAT GTT CCT 
CAG GCA G-3’ (2961 F2) and 5’-CTC TAT GGC CTC CTA CAT CTG-3’ (2961 R2), 
5’-TGA GTT CTG GCT TTC AGG AG-3’ (3072 F3) and 5’-GAT CTT GTC TTC ATT 
CAC CTT G-3’ (3072 R3). Real-time PCR amplification reactions were performed using 
SYBR Green detection chemistry and run as triplicate samples on 96-well plates using 
the CFX 96TM Real-Time PCR Detection System (Bio-Rad). The PCR reactions were 
prepared in a total volume of 25μl containing: 5μl of Chip or input template DNA, 2μl of 
each amplification primer (final concentration 50nM), and 12.5μl of 2Х iQ SYBR Green 
Supermix (Bio-Rad). The cycling conditions were set as follows: an initial denaturation 
step of 95 °C for 10 min to activate the iTaq DNA polymerase, followed by 40 cycles of 
denaturation at 95 °C for 15 s, and annealing at 60 °C for 1 min. The amplification 
process was followed by a melting curve analysis, ranging from 65 °C to 95 °C, with 
temperature increasing at steps of 2°C every 1 min. Baseline and threshold cycles (Ct), 
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were automatically determined using the Bio-Rad CFX Manager 2.1. The samples were 
electrophoresed on a 1.5% (w/v) agarose gel, and the banding pattern observed under UV 
light. Two biological replicates for each sample were used for real-time PCR analysis and 
three technical replicates were analyzed for each biological replicate. 
 
Blocking TNFR Activation of IDO1 Biosynthesis 
Peptides containing the CD40 receptor TRAF2, 3 and TRAF6 binding sites were 
linked to the TAT47–57 cell penetrating peptide. The sequences for the CD40–TRAF2, 3 
and the CD40–TRAF6 blocking peptides were NH2- 
NTAAPVQETLHGYGRKKRRQRRR-OH and NH2- KQEPQEIDFPDD 
YGRKKRRQRRR-OH respectively. The TAT47–57 sequence is underlined. Control 
peptides consisted of either TAT47–57 alone or TAT47–57 linked to a scrambled 
peptide. The peptides were manufactured by Proteintech Group (San Diego, CA) and 
were low in endotoxin and > 98% pure as measured by HPLC (Portillo, Greene, 
Schwartz, Subauste, & Subauste, 2015; J. A. Portillo et al., 2014). 
 
CTB-INS Amino Acid Sequence Alignment with TNF Receptor Family Members 
The protein amino acid sequence of CTB-INS (FASTA sequence- 
MIKLKFGVFFTVLLSSAYAHGTPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKR 
EMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNN 
KTPHAIAAISMANGPGPFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDL 
QVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCNSEKDE), 
was aligned with the following tumor necrosis factor (TNF) superfamily member ligands: 
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CD40L (Accession: NP_000065.1), TNFR14 (Accession: NP_003798.2), RANKL 
(Accession: NP_003692.1), and BAFF (Accession: NP_006564.1) using the T-Coffee 
server (http://tcoffee.crg.cat) (Notredame, Higgins, & Heringa, 2000). The protein 
alignment graphics were constructed using Jalview software v1.6 (Waterhouse, Procter, 
Martin, Clamp, & Barton, 2009). 
 
Results 
IDO1 Expression Following CTB-INS Incubation 
Concentrations of 0.1-10μg/ml CTB-INS were used to assess the minimal 
concentration of CTB-INS needed to allow detection of IDO1 in monocyte-derived DCs. 
Expression of IDO1 induced by CTB-INS occurred at concentrations as low as 0.5μg/ml 
of CTB-INS (Figure 2.2A). Monocyte-derived DCs were incubated with CTB-INS for 6 
to 96 hours with the medium replaced at 2 day intervals. The levels of IDO1 in vaccine 
inoculated DCs increased continuously for 96 hours following vaccination (Figure 2.2B). 
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Figure 2.2. IDO1 Expression with varying concentrations of CTB-INS and incubation 
times and conditions. In panel (A) varying concentrations of CTB-INS from 0.1 to 10μg/ml 
were used to assess the minimal concentration of CTB-INS needed to cause detection of 
IDO1 in monocyte-derived DCs. In Panel (B) monocyte-derived DCs were incubated with 
CTB-INS for 6 hours to 96 hours with the medium changed every 2 days. IDO1 expression 
went increasingly unabated for 96 hours. M: Marker. PC: Positive Control (IDO1 
recombinant protein) NC: Negative Control (Untreated). 
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CTB-INS Stimulation of the Non-canonical NF-κB Pathway Induces IDO1 
Synthesis in DCs 
To assess non-canonical NF-κB pathway contributions to CTB-INS-induced 
IDO1 expression we used siRNA technology to knock down the non-canonical pathway 
dependent kinase NIK and measured the level of IDO1 expression in treated DCs. The 
knockdown of NIK in CTB-INS stimulated DCs resulted in a significant reduction in 
NIK mRNA levels (Figure 2.3A) and IDO1 protein expression as well as a decrease in 
phosphorylated IKKα in comparison with non-specific siRNA-treated dendritic cells 
(Figure 2.3B). This experimental result demonstrated that CTB-INS-induced IDO 
expression in human DCs was dependent upon vaccine activation of the non-canonical 
NF-κB pathway. 
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Figure 2.3. The non-canonical NF-κB pathway is required for CTB-INS-induced IDO1 
expression in monocyte-derived DCs. Panel (A) shows NIK mRNA levels in monocyte-
derived DCs transfected with NIK-specific siRNA (siNIK) or negative control (siC) 
examined by RT-PCR using NIK specific primers. The β-actin gene was used as an internal 
standard in RT-PCR. This image is representative of two independent experiments. Panel 
(B) graphic representation of NIK mRNA levels in CTB-INS vaccinated and unvaccinated 
DCs. Panel (C) shows the expression of IDO1 protein and phosphorylated IKKα in moDCs 
transfected with NIK-specific siRNA (siNIK) or negative control (siC) examined by 
Western blot analysis using anti-IDO1 as the primary antibody. This image is 
representative of three independent experiments. Panel (D) shows graphic representation 
of the cell viability of non-transfected or transfected with NIK-specific siRNA (siNIK) or 
negative control (siC) in mDCs. Dendritic cell viability was measured by determination of 
the percentage of vaccinated DCs negative for annexin V and propidium iodide. NT means 
non-siRNA CTB-INS transfected DCs, and – or + means without or with CTB-INS. 
Samples were assayed in triplicates and the results represent the mean ± SD of three 
independent experiments p < 0.01. Statistical analysis was performed using one way 
analysis of variance (ANOVA). 
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CTB-INS Leads to Non-Canonical NF-κB RelB Translocation to Drive IDO1 
Expression in DCs in vivo 
The IDO1 promoter region was shown to contain three partial RelB/p52 binding 
sites (AGGAGACACA, GGGAGACAGA, and AGGAGAAAGA), with a consensus 
non-canonical binding sequence PuGGAGApyTTPu located close to position -2000 
(Figure 2.4A), (Bonizzi & Karin, 2004; Manches et al., 2012; Puccetti & Grohmann, 
2007). To demonstrate direct binding of RelB/p52 to the IDO1 promoter, we performed a 
ChIP analysis experiment using RelB binding to pull-down the IDO1 promoter (Figure 
2.4B). Immunoprecipitation of RelB induced by CTB-INS showed binding to all three 
IDO1 non-canonical binding sequences with increased binding at the GGGAGACAGA 
promoter sequence (Figure 2.4B, C). 
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Figure 2.4. ChIP analysis showing vaccine stimulation of NF-κB RelB binding to the 
human dendritic cell IDO1 promoter region in vivo. Panel (A) shows the sequence of three 
partial non-canonical NF-κB RelB binding sites in the IDO1 promoter (capitalized 
nucleotides). The arrows indicate the primer sequences for detection of the three RelB 
binding sites. Panel (B) shows the PCR products after chromatin immunoprecipitation 
(ChIP). Immature human DCs were stimulated with the CTB-INS fusion protein vaccine 
for 0 (-) or 6 hr (+). Protein-DNA complexes were cross-linked, the DNA sheared and RelB 
genomic DNA complexes immunoprecipitated with RelB monoclonal antibody. After 
purification of the DNA, Real-time PCR was performed using primers flanking the three 
consensus NF-κB RelB binding sites in the human IDO1 promoter region shown in panel 
A. The Input control consists of PCR amplification of the IDO1 promoter obtained from 
total genomic DNA prior to immunoprecipitation. Lane M: DNA fragment size marker, 
Lanes 1, 2, 3: show the products of PCR amplification with primer sets detecting the three 
consensus RelB binding sites in the vaccinated human IDO1 promoter region (white 
arrows). Panel (C) Quantification of immunoprecipitation was performed for three 
experiments, by normalizing the intensity of each immunoprecipitated band to its input. 
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Vaccine Stimulation of the TNFR Signaling Pathway Induces IDO1 Biosynthesis in 
Human DCs 
Control of NIK post-translational stability may be essential for non-canonical NF-
κB signaling modulation. Therefore, the control of NIK stability is one of the prime 
questions for understanding regulation of the non-canonical NF-κB signaling pathway. 
Mounting evidence suggests that TNF receptor-associated factors, TRAF2, TRAF3 and 
TRAF 6, are critical molecules involved in negative regulation of NIK activity (Hostager 
& Bishop, 2013; Song & Kang, 2010; Vallabhapurapu et al., 2008). (Figure 2.5). 
Pharmacological inactivation of these proteins or their deletion also allows for basal NIK 
accumulation in the absence of ligand (Elgueta et al., 2009; Portillo et al., 2015; J. A. 
Portillo et al., 2014; Sun, 2010, 2011; Xiao et al., 2004; Xiao et al., 2001). 
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Figure 2.5. Activation of the non-canonical NF-κB pathway. In the basal inactive state 
(left), the TRAF-cIAP complex catalyzes ubiquitination of NIK, leading to constitutive 
NIK degradation in the proteasome leaving p100-containing RelB complexes isolated in 
the cytoplasm. During activation (right), the TRAF-cIAP complex is recruited to the CD40 
receptor. Upon ligand binding, TRAF2-mediated, ubiquitination of cIAP1/2 switches its 
ubiquitin ligase activity from NIK to TRAF3. The resultant TRAF3 degradation 
destabilizes the TRAF-cIAP complex allowing accumulation of newly synthesized NIK. 
Phosphorylated NIK then transfers a phosphate to IKKα. Now activated, IKKα 
phosphorylates p100 leading to its partial proteosomal degradation releasing p52: RelB 
heterodimers that translocate into the nucleus. Further, activated IKKα phosphorylates 
NIK, destabilizing it thereby limiting downstream activation events. 
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The engagement of CD40 by CD40L promotes clustering of CD40 inducing the 
recruitment of adapter proteins known as TNFR-associated factors (TRAFs) to the 
cytoplasmic domain of CD40 (Elgueta et al., 2009). Previous reports showed that cell 
permeable peptides that include the TRAF2, 3 or TRAF6 binding site to CD40 are able to 
block the CD40-TRAF signaling pathway (Chatzigeorgiou et al., 2014; Chatzigeorgioua 
et al., 2014; Elgueta et al., 2009; Lutgens, 2012; Portillo et al., 2015; J. A. C. Portillo et 
al., 2014; Vallabhapurapu et al., 2008). Inhibition of the TNFR pathway permits 
examination of its role in induction of IDO1 in vaccinated dendritic cells. Therefore, 
monocyte-derived DCs were incubated with peptides containing the amino acid sequence 
of the TRAF2, 3 and the TRAF6 binding sites to CD40. The DCs were then stimulated 
with CD40 ligand (CD154), and CTB-INS. The CD40-TRAF2, 3 and CD40-TRAF6 
blocking peptides were shown to impair upregulation of IDO1 in response to CD154, and 
CTB-INS treatment. The most impairment of IDO upregulation was detected when both 
TRAF 2, 3 and TRAF 6 inhibitors were used in combination. (Figure 2.6). 
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Figure 2.6. The TNFR-TRAF pathway is required for CTB-INS vaccine induction of IDO1 
protein biosynthesis. In Panels (A,B,C) monocyte-derived DCs were inoculated with 
blocking peptides containing the amino acid sequence of TRAF2, 3 or TRAF6 binding 
sites of CD40 linked to the TAT47–57 membrane transport peptide. After blocking peptide 
binding, the DCs were stimulated with 500ng/ml of CD40L (CD154), Immunex, Seattle, 
WA), LPS (1μg/ml) and CTB-INS (10μg/ml). Both CD40-TRAF2, 3 and CD40-TRAF6 
blocking peptides impaired upregulation of IDO1 in response to CD154, LPS and CTBINS. 
Each image is representative of two independent experiments. (D) Relative cell viability 
of cells treated with CTB-INS in combination with TRAF 6BP and TRAF 2, 3 BP. 
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CTB-INS as a Ligand for Members of the TNFR Superfamily 
Members of the Tumor Necrosis Factor (TNF) receptor family have been shown 
to stimulate DC maturation or modulate peripheral tolerance in autoimmunity by 
upregulation of IDO1 (Coope et al., 2002; Ma & Clark, 2009; Tas et al., 2007). Both 
CTB and LTB enterotoxin protein binding subunits were shown to stimulate antigen 
presenting cell CD40 surface expression and DCs were found to upregulate IDO1 
mediated immune suppression through activation of the NF-κB non-canonical signaling 
pathway (Tas et al., 2007). Protein functional homology analysis (PROPSEARCHTM) 
identified the probability of functional homology between CTB-INS and the TNF 
subfamily of ligands to be >87%, (unpublished data). Based on the data in (Figure 2.6) 
we hypothesize that CTB-INS interacts with TNF receptors to stimulate IDO1 synthesis 
in vaccinated DCs. To test this hypothesis, we aligned CTB-INS protein amino acid 
sequence with the following tumor necrosis factor (TNF) superfamily member ligands: 
CD40L (Accession: NP_000065.1), TNFR14L (Accession: NP_003798.2), RANKL 
(Accession: NP_003692.1), and BAFF (Accession: NP_006564.1) using the T-Coffee 
server. We observed that the CTB-INS vaccine shares significant levels of amino 
sequence homology with ligands of the TNFR superfamily (Figure 2.7). 
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Figure 2.7. Comparison of the amino acid sequence of CTB-INS with ligands of the Tumor 
Necrosis Factor Receptor (TNFR) superfamily (CD40L, TNF14, RANKL and BAFF). The 
light-blue horizontal line corresponds to the amino acid sequence of CTB and the dark blue 
horizontal line denotes the amino acid sequence of proinsulin. The black boxes highlight 
areas of greater functional binding homology among TNFR family members, in which the 
red highlighted areas signify greater levels of amino acid homology and the green areas, 
low to no detectable homology. 
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Discussion 
The mechanism of CTB-INS induction IDO1 biosynthesis was shown to be 
dependent on the NF-κB signaling pathway (J. C. Mbongue et al., 2015). However, the 
relative contributions of canonical and non-canonical branches of this pathway to IDO1 
up regulation remain unknown. Earlier work by Tas and his colleagues showed that 
CD40L was responsible for stimulation of IDO1 via the non-canonical pathway (Tas et 
al., 2007), suggesting this pathway could play a significant role in CTB-INS induction of 
IDO1 in human DCs. Based on NIK-dependent activation experiments, our data suggest 
CTB-INS induces IDO1 in human monocyte-derived DCs via the non-canonical NF-κB 
pathway. In addition, ChIP analysis experiments showed that NF-κB RelB-p52 dimers 
bound to defined consensus sequences within the IDO1 promoter in vivo, suggesting the 
non-canonical signaling pathway is active in vaccine induction of IDO1 in human DCs. 
Blocking TRAF adaptor molecule functions was shown to inhibit IDO1 biosynthesis in 
vaccinated DCs suggesting upregulation of IDO may occur through TNF receptor family 
stimulation of the NF-κB non-canonical signal transduction pathway (Song & Kang, 
2010). In the TNF-activated signal transduction pathway, NIK is known to interact with 
TRAF2, and TRAF3 leading to non-canonical NF-κB activation (Vallabhapurapu et al., 
2008). 
Induction of IDO1 depends on fusion of CTB to proinsulin (J. C. Mbongue et al., 
2015), suggesting that the vaccine may bind as a ligand to receptors responsible for NF- 
κB non-canonical pathway activation of IDO1 expression. Several ligands of the Tumor 
Necrosis Family Receptor (TNFR) superfamily were shown to activate the non-canonical 
NF-κB pathway (Bishop, Moore, Xie, Stunz, & Kraus, 2007; Hsu et al., 1997; Morrison, 
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Reiley, Zhang, & Sun, 2005; Novack et al., 2003; Tas et al., 2007; Theill, Boyle, & 
Penninger, 2002). For suggestive evidence of a link between CTB-INS with TNFR, we 
compared amino acid sequences of CTB-INS with those of four ligands of the TNFR 
family to assess any type of functional homology. We found that several areas where the 
vaccine could act as a TNFR ligand, represented by areas of greater amino acid 
homology (Figure 2.7). 
The association between the ligand and its potential receptor suggests that 
CTBINS receptor binding may involve specificity of the autoantigen for its receptor 
rather than existing as a general mechanism for binding all CTB-autoantigen conjugates. 
Our experimental data suggests that CTB-INS induces non-canonical NF-κB signaling 
which is driven by TRAFs as TNFR signal mediators. Although, there is evidence that 
CTBINS elicits immunosuppressive effects through TNFRs, further experiments are 
needed to determine the probability of CTB-INS binding to individual members of the 
TNFR family. 
The B-cell activating factor (BAFF) predominantly expressed in B cells, differs 
from many other TNFR superfamily members in that it generally activates the non-
canonical NF-κB signaling pathway with only weak induction of canonical NF-κB 
pathway signaling (Claudio, Brown, Park, Wang, & Siebenlist, 2002; Morrison et al., 
2005). This unique feature of the BAFF receptor (BAFFR) is due primarily to its 
possession of an atypical TRAF-binding sequence, which interacts with TRAF3 but not 
with TRAF2 (Morrison et al., 2005). The BAFFR-mediated induction of p100 processing 
to p52 contributes to the survival of transitional and mature B cells, likely through 
induction of anti-apoptotic genes like bcl-2 and bcl-x (Claudio et al., 2002; Morrison et 
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al., 2005). 
The CD40 molecule is a TNFR member expressed on a variety of cell types, 
including B cells, dendritic cells, monocytes, endothelial epithelial cells, and neurons 
(Bishop & Hostager, 2003; Ma & Clark, 2009). Activated T cells primarily express the 
ligand of CD40, alternatively referred to as CD40L or (CD154). In the immune system, a 
major function of CD40 signaling is to regulate B-cell activation and differentiation 
events, including proliferation and survival of activated B cells, germinal center 
formation, and antibody isotype switching. Another major function of CD40 is to mediate 
dendritic cell maturation and antigen presentation. Unlike BAFFR, CD40 elicits strong 
signals that target both the canonical and non-canonical NF-κB pathways (Ma & Clark, 
2009; Tas et al., 2007). Upon ligation by CD40L, CD40 interacts via two different 
TRAF-binding motifs that include TRAF1, 2, 3, 5, and 6, and this interaction leads to 
proteolysis of both TRAF2 and TRAF3 (Bishop et al., 2007; Harnett, 2004). As indicated 
above, the degradation of TRAF2 and TRAF3 represent an important step in the 
activation of the non-canonical NF-κB signaling pathway (Sun, 2010, 2011; Sun & Ley, 
2008). 
The herpesvirus entry mediator (HVEM) or tumor necrosis factor receptor 
superfamily member 14 (TNFRSF-14) is a protein originally known as herpesvirus entry 
mediator A (HveA). Both HveB and HveC are structurally unrelated proteins of the 
immunoglobulin superfamily (Montgomery, Warner, Lum, & Spear, 1996). HvA is also 
known as CD270 (Hsu et al., 1997). Moreover it is also referred to as ATAR (another 
TRAF-associated receptor). Interactions between TNFRSF- 
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14 and TRAF2 were shown to activate the non-canonical NF-κB signaling pathway (Hsu 
et al., 1997). 
The Receptor Activator of Nuclear Factor κ B (RANK) is best known for its role 
in osteoclastogenesis (Novack et al., 2003; Sun, 2011). However, it also regulates 
important immune functions that include dendritic cell survival and lymphoid 
organogenesis (Theill et al., 2002). RANK is expressed on osteoclast precursors, 
dendritic cells, and activated B cells, and in general, RANK signaling was shown to 
promote cell survival and differentiation. Analogous with CD40, the cytoplasmic domain 
of RANK was shown to bind TRAF1, 2, 3, 5, and 6 and mediates activation of both 
canonical and non-canonical NF-κB signaling pathways. Genetic evidence suggests an 
essential role for RANK-stimulated activation of non-canonical NF-κB activation during 
osteoclastogenesis and bone metabolism (Novack et al., 2003). The non-canonical NF-κB 
has been closely linked to immune suppression (J. C. Mbongue et al., 2015; Pallotta et 
al., 2011). Several ligands such as Glucocorticoid-induced tumor necrosis factor receptor 
(GITR) on T cells and its natural ligand, GITRL, on accessory cells contribute to the 
control of immune homeostasis. Grohmann et al. showed that reverse signaling through 
GITRL after engagement by soluble GITR initiates the immunoregulatory pathway of 
tryptophan catabolism in mouse plasmacytoid dendritic cells, by means of noncanonical 
NF-κB–dependent induction of IDO1 (Grohmann et al., 2007). Additionally, CpG-rich 
oligodeoxynucleotides activate the immune system, leading to innate and adaptive 
immune responses that have been shown to promote tolerogenic responses in mouse 
plasmacytoid dendritic cells in vivo and in an in vitro human DC model. Unveiling a 
previously undescribed role for TRIF and TRAF6 proteins in Toll-like receptor 9 (TLR9) 
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signaling, it was demonstrated that physical association of TLR9, TRIF and TRAF6 leads 
to activation of non-canonical NF-κB signaling and the induction of IRF3- and TGF-β-
dependent immune-suppressive tryptophan catabolism (Volpi et al., 2013). 
Understanding the link between vaccine activation of TNF receptor family 
members and the activation of non-canonical NF-κB signaling is an important step in 
elucidation of the mechanism underlying chimeric vaccine induction of immunological 
tolerance in dendritic cells. Understanding the mechanism of chimeric vaccine 
modulation of IDO1 induction and suppression of in human dendritic cell activation will 
facilitate development of chimeric vaccine strategies for effective and safe therapy for 
type 1 diabetes and a wide range of tissue specific autoimmune diseases. 
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Abstract 
Fusion of the cholera toxin B subunit fusion to autoantigens such as proinsulin 
(CTB-INS), down regulate dendritic cell (DC) activation and stimulate the synthesis of 
DC immunosuppressive cytokines. Recent studies of CTB-INS-induced immune 
tolerance in human DCs show that increased synthesis of tryptophan catabolic enzyme 
indoleamine 2, 3- dioxygenase (IDO1) may play an important role in CTB-INS vaccine 
suppression of DC activation.  Studies in murine models of autoimmunity suggest 
transforming growth factor beta (TGF-β) may be involved in the stimulation of IDO1 
biosynthesis, for induction of immunological tolerance in DCs. In this study, we 
investigated the contribution of TGF-β superfamily proteins to CTB-INS induction of 
IDO1 biosynthesis in human monocyte-derived DCs (moDCs). The fusion protein was 
shown to upregulate levels of TGF-β1, activin-A and the TGF-β activator, integrin αvβ8 
in human DCs. The CTB-INS fusion protein was also shown to induce Smad2/3 
phosphorylation; However, inhibition of endogenous TGF-β, activin-A or addition of 
biologically active TGF-β1, and activin-A, did not inhibit or stimulate IDO1 biosynthesis 
in human DCs treated with CTB-INS. While kinase inhibition with the inhibitor, RepSox, 
blocked Smad2/3 phosphorylation and diminished IDO1 biosynthesis in a concentration 
dependent manner, inhibition of TGF-β type 1 kinase receptor function with SB-431542 
did not arrest IDO1 biosynthesis, suggesting involvement of a kinase pathway other than 
TGF-β type 1 kinase in CTB-INS induction of IDO1 in human moDCs. Together, our 
experimental findings identify alternative immunoregulatory proteins induced by CTB-
INS fusion protein that suggest CTB-INS may utilize multiple mechanisms for induction 
of immune tolerance in human moDCs. 
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Introduction 
The condition of autoimmunity is represented by a group of progressive chronic 
inflammatory diseases in which cells of the immune system induce a systemic or organ 
specific immune response against self-antigens. Autoimmunity generally attacks more 
women than men and affects 7-10% of the U.S. population (Agmon-Levin et al., 2011; 
Miller et al., 2012; Whitacre, 2001). Cells of the innate portion of the immune system are 
involved not only in the initiation of an immune response to pathogens but also in the 
initiation of autoimmune disease pathogenesis (Peng and Tian, 2014). Dendritic cells 
(DCs), considered to be the dominant antigen-processing and presenting cells of the 
body, are central to the regulation of innate and adaptive immune responses responsible 
for the maintenance of immune homeostasis (Raker et al., 2015). One major function of 
DCs is the processing and presentation of foreign and self-antigens to naive T cells 
resulting in the induction of T cell differentiation into either pro- or anti-inflammatory T 
cell populations. A break down in these normal DC functions can result in immunological 
impairment that includes autoimmunity and other chronic inflammatory diseases 
(Hammer and Ma, 2013; Thome et al., 2014). The tolerogenic functions of DCs have a 
therapeutic potential for prevention and treatment of autoimmune diseases, organ 
transplant rejection and other conditions of immune dysregulation that result in chronic 
inflammation(Osorio et al., 2015).  Dendritic cells are known to induce immunological 
tolerance through the induction of T cell anergy, apoptosis or stimulation of regulatory T 
cell (Treg) proliferation. To alter the immune environment, the DC may express 
tolerogenic factors like IDO1 to regulate T cell differentiation and proliferation 
(Maldonado and von Andrian, 2010; Raker et al., 2015).  
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Type 1 diabetes (T1D) is a prototypic and economically important tissue specific 
autoimmune disease, in which loss of tolerance to islet-derived antigens, initiates 
autoreactive effector T cell (Teff) mediated destruction of the insulin-producing β cells 
located in the pancreatic islets of Langerhans (Morel, 2013).  In the absence of insulin 
replacement therapy T1D leads to permanent insulin deficiency, diabetic coma and death. 
Considering the critical role dendritic cells play in maintenance of self-tolerance and in 
subverting autoimmunity, they have recently become the subjects of strategies designed 
to mediate therapy for autoimmune diseases. The application of DC mediated restoration 
of immunological tolerance holds particular promise for prevention of autoimmune 
disease onset and progression (Thomas, 2013). 
A chimeric fusion protein vaccine composed of the cholera toxin B subunit linked 
at its c-terminus to the diabetes autoantigen proinsulin (CTB-INS), was shown to 
suppress autoimmune diabetes development in the non-obese diabetic (NOD) mouse 
(Arakawa et al., 1998; Aspord and Thivolet, 2002; Dénes et al., 2006).   Further 
investigations using human monocyte-derived dendritic cells (moDCs) showed that 
vaccine efficacy depended on inhibition of dendritic cell activation through, suppression 
of DC costimulatory molecules, CD86 and CD80, suppression of pro-inflammatory 
cytokines and induction of the immunosuppressive tryptophan catabolic enzyme, 
indoleamine 2, 3-dioxygenase (IDO1) (Mbongue et al., 2015; Odumosu et al., 2011b). 
IDO1 catalyzes the breakdown of the essential amino acid tryptophan into degradation 
products called kynurenines and modulates immune suppression and peripheral tolerance 
(Fallarino et al., 2012; Harden and Egilmez, 2012). For example, in mice, T cell 
sensitivity to IDO1 reduction of tryptophan levels, inhibits their proliferation (Munn et 
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al., 2005). Further, the expression of IDO1 in human moDCs induces a state of immune 
tolerance through inhibition of pro-inflammatory T cell proliferation (Hwu et al., 2000; 
Planès and Bahraoui, 2013) and by the generation of regulatory T cell populations 
(Chung et al., 2009; Jürgens et al., 2009). The anti-inflammatory response of DCs to 
vaccine action may be significant in preventing the onset of type 1 diabetes (T1D). 
However, elucidation of the mechanism of immune suppression mediated by CTB-INS is 
required for validation of vaccine efficacy and safety prior to its use in therapy against 
T1D.   
The Transforming Growth Factor-beta (TGF-β) superfamily is a group of 
pleiotropic cytokines that function in a variety of crucial biological activities that include 
cell growth and differentiation, cell death, early embryonic development, tumorigenesis, 
tissue homeostasis, immune responses and the regulation of inflammation (Isabel et al., 
2014; Wakefield and Hill, 2013; Wijayarathna and de Kretser, 2016).The TGF-β 
superfamily includes the TGF-βs, activins, bone morphogenetic proteins (BMP), 
NODAL, growth and differentiation factors (GDF) and anti-Müllerian hormone (AMH), 
which make up the major subfamilies of up to 33 identified members encoded in the 
human genome (Morikawa et al., 2016; Moustakas and Heldin, 2009; Wakefield and Hill, 
2013).  
The TGF-β superfamily ligands transmit molecular signals by a mechanism 
conserved across all the members of the family. TGF-β signaling is initiated by binding 
of the ligand to its type II receptor which results in the recruitment of a type I receptor to 
form a type 2-type 1 receptor complex. The type I and type II cell surface receptors are 
transmembrane serine/threonine kinases, and upon receptor complex formation, the type I 
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receptor becomes phosphorylated and subsequently phosphorylates specific cytoplasmic 
transcription factor proteins called receptor-regulated Smads (R-Smads) (Huminiecki et 
al., 2009; Massague, 1998; Weiss and Attisano, 2013). The Smad proteins are the 
intracellular core machinery responsible for transducing external signals from TGF-β 
ligands through their receptors into the nucleus of the cell resulting in transcription of 
specific gene products. The R-Smads, Smad1, Smad5, and Smad8, are activated by the 
BMP/GDF pathway, while Smad2 and Smad3 are mainly activated by TGF-β, activin, 
and NODAL type I receptors (Huminiecki et al., 2009; Massagué, 2012; Moustakas and 
Heldin, 2009). Phosphorylation of the R-Smads results in their association with a 
common-mediator-Smad (Co-Smad) called Smad4. This association forms an R-Smad-
Smad4 complex that translocates to the nucleus where it can associate with other DNA-
binding transcription factors, to form a protein complex capable of binding to specific 
enhancer and promoter regions in a target gene to activate or repress transcription 
(Licona-Limón and Soldevila, 2007; Massague, 1998). 
The TGF-β superfamily cytokines have been shown to modulate adaptive and 
innate immune responses. These cytokines critically regulate T cell differentiation and 
maturation, act synergistically to induce regulatory T cells (Tregs), mediate DC functions 
and natural killer cell-DC interactions, regulate macrophage polarization and attenuate 
pro-inflammatory cytokines (Licona-Limón and Soldevila, 2007; Lu et al., 2010; Robson 
et al., 2007; Seeger et al., 2014; Wang et al., 2014). The prototypic member of the TGF-β 
superfamily, TGF-β1, has been identified as a critical cytokine involved in the regulation 
of DC immune responses and in the maintenance of immune cell homeostasis via 
mechanisms of immune defense and/or recovery from autoimmune diseases (Li et al., 
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2006b; Prud'homme and Piccirillo, 2000). Deficiency of the TGF-β1 gene, and gene 
deletions in the TGF-β1 signaling pathway in mice, results in multifocal inflammatory 
autoimmune disorders, or inflammatory states that mimic several autoimmune diseases 
(Aoki et al., 2005; Kriegel et al., 2006; Prud'homme and Piccirillo, 2000).  
Despite the pleiotropic functions of TGF-β1, it is a tightly regulated cytokine: 
TGF-β1 is secreted and maintained as an inactive complex that requires activation to 
become functional (Hammer and Ma, 2013; Mu et al., 2002).  The TGF-β1 cytokine is 
synthesized as a homodimeric pro-peptide consisting of the active TGF-β1 covalently 
linked to the latency associated peptide (LAP). Following enzymatic cleavage in the 
Golgi, the LAP remains attached to the mature TGF-β1 by non-covalent bonds in an 
association called the small latent complex (SLC) (Li et al., 2006b; Wipff and Hinz, 
2008; Worthington et al., 2012). This interaction prevents the active TGF-β1 from 
binding to its receptors. Disassociation of the active peptide from LAP is termed latent 
TGF-β activation and can be mediated in biological systems by several proteases and cell 
transmembrane molecules called integrins (Travis and Sheppard, 2014). Members of the 
αv integrin family recognize specific arginine-glycine-aspartate (RGD) sequences present 
on LAP by which they bind to the latent TGF-β complex and liberate the active TGF-β to 
interact with its receptors (Song et al., 2016). The binding of the αv integrin family to the 
RGD is critical for TGF-β activation in maintaining immune regulation as mice with 
mutated binding sequences phenocopy TGF-β-null mice, dying from multi-organ 
inflammatory conditions (Yang et al., 2007). Integrin αvβ8 is the only αv member that 
has been detected on murine immune cells. The integrin is expressed only on murine DCs 
and CD4+ T cells but absent from other immune cells and has a critical role in 
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maintaining immune homeostasis by promoting TGF-β activation and signaling (Travis 
et al., 2007b; Worthington et al., 2015). 
Studies on murine dendritic cells have revealed that IDO-dependent induction of 
tolerance in murine DCs requires TGF-β1, which both induces and maintains IDO 
synthesis in murine DCs by signaling that involves PI3/Akt phosphorylation and non-
canonical NF-κB activation (Belladonna et al., 2008; Pallotta et al., 2011). Recent studies 
in our laboratory showed that CTB-INS induction of IDO1 biosynthesis in human 
moDCs involved non-canonical NF-κB activation (Kim et al., 2016). Therefore, in order 
to elucidate the mechanism by which CTB-INS induces immunological tolerance in 
human moDCs, we evaluated the role of TGF-β superfamily members in the induction of 
IDO1 biosynthesis in human moDCs following vaccination with CTB-INS. We analyzed 
IDO1 expression and Smad2/3 phosphorylation, following inhibition of Smad2/3 
signaling in CTB-INS treated moDCs. 
 
Materials and Methods 
Preparation of Peripheral Blood Mononuclear Cells 
This experimental study was approved by the Loma Linda University IRB and 
Research Ethics Committees. Experiments on peripheral blood mononuclear cells 
(PBMCs) were performed ex-vivo, with aphaeresis blood provided by the Life Stream 
Blood Bank (San Bernardino, CA) with blood donor consent. Blood donor information 
was anonymized before initiation of the study. 
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Synthesis and Isolation of CTB-INS Fusion Protein 
The Escherichia coli producer strain, BL-21 (DE3) pLysS (Invitrogen, Carlsbad, 
CA), transformed with the CTB-INS fusion gene, was grown in 250 ml Luria Broth (LB) 
medium containing ampicillin (100mg/ml) with shaking at 37oC for 7 to 8 hours. CTB-
INS protein synthesis in the bacterial culture was stimulated with 2.0mM isopropyl β-D-
1-thiogalacto-pyranoside (IPTG), (Sigma Chemical Co. St Louis, Mo) at 3 hours of 
culture, and the CTB-INS protein extracted  as previously described (Odumosu et al., 
2011b) (Figure 1). Briefly, the bacterial cells were harvested at optimal culture density of 
up to 0.2-0.4 O.D.600, and CTB-INS protein was isolated from the bacterial cell 
homogenate using Maxwell Model 16 robotic protein purification system (Promega, Inc.) 
according to the manufacturer’s instructions. The elution buffer was removed by dialysis 
at 4°C in phosphate buffered saline (PBS) and the purity of the isolated protein was 
determined by polyacrylamide gel electrophoretic mobility analysis followed by 
immunoblotting (Western) with anti-Cholera Toxin as the primary antibody (Sigma, Inc).  
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Figure 3.1. Gene construct and protein isolation of CTB-INS fusion protein. Panel (A) 
Plasmid map of the E. coli expression vector, pRSET A (Invitrogen, Carlsbad, CA), 
carrying the CTB-INS fusion gene. The expression vector is under the control of the 
bacteriophage T7 promoter and contains an oligonucleotide region that encodes 6 histidine 
amino acid residues immediately 5’ upstream of the CTB gene sequence. The CTB-INS 
fusion protein was expressed using the E. coli pRSET A expression vector and purified by 
nickel binding isolation of the recombinant protein using a Maxwell 16 protein isolation 
robot (Promega Inc, Madison, WI, USA). (B) SDS-PAGE of CTB-INS protein visualized 
by Coomassie staining. Lane MW: protein size marker (BIO-RAD, Hercules, CA); 1: non-
induced E. coli (BL-21) cell lysate; 2: IPTG induced E. coli lysate; 3: Eluted CTB-INS 
protein; 4: Eluted CTB-INS protein. (C) Immunoblot of recombinant CTB-INS fusion 
protein detected with anti-CTB primary antibody. Lane 3: Eluted CTB-INS protein; 4: 
Eluted CTB-INS protein.   
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Monocyte Isolation and Differentiation of DCs 
Monocytes were isolated from peripheral blood using LS separation columns and 
anti-CD14 magnetic MicroBeads (Miltenyi Biotec) as previously described (Mbongue et 
al., 2015) and maintained in culture at a density of 5 x 105 to 1 x 106 cells/ml. Immature 
DCs were differentiated from CD14 positive monocytes by incubation for 6 days in 
RPMI 1640 medium (Hyclone, GE Healthcare Life Sciences) containing 10% FBS and 
supplemented with human GM-CSF (50ng/ml) and human IL-4 (10ng/ml) (Miltenyi 
Biotec).  Half the medium was replaced with fresh medium every 2 days being careful 
not to dislodge the cells from the substrate. 
 
Dendritic Cell Treatments 
The differentiated immature moDCs (assessed by observation of dendrite formation 
using phase contrast microscopy) were incubated with 5µg/ml of CTB-INS protein or 20-
100ng/ml recombinant bioactive human TGF-β1 (e-Bioscience), or 10-100ng/ml 
recombinant human activin-A (e-Bioscience) for 24hrs at 37oC. To inhibit TGF-β 
signaling, the moDCs were treated with CTB-INS vaccine in the presence or absence of 
RepSox (12.5µM or 25µM; SIGMA), or the specific TβRI serine/threonine kinase 
inhibitor, SB-431542 (10µM; Reagents Direct) or DMSO as negative control, added 1hr 
before treatment with CTB-INS vaccine. To neutralize the presence of active TGF-β 
cytokine, the moDCs were pre-incubated for 15min to 1hr at 37°C with a pan-TGF-β 
(TGF-beta 1, 2, 3) neutralizing antibody clone 1D11 (20µg/ml; from R&D Systems, 
Minneapolis, MN, USA) or mouse IgG1 isotype control clone 11711 (R&D Systems, 
Minneapolis, MN, USA) (Belladonna et al., 2008) followed by treatment with CTB-INS 
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fusion protein (5µg/ml) for 24hrs. For neutralization of activin, the moDCs were 
incubated with recombinant human follistatin 288 (100-400ng/ml; R&D Systems, 
Minneapolis, MN, USA). 
 
Real Time PCR Analysis 
CTB-INS (5ug/ml) treated and untreated DCs were harvested at 1hr, 3hr, and 6hr 
time points. DCs incubated with the vaccine vehicle served as untreated controls. Total 
RNA was extracted from the DCs using RNA-STAT 60 isolation protocol (Tel-Test, 
Friendswood, TX). Total RNA concentration was measured using a NanoDrop 
2000/2000c Spectrophotometer (Thermo Scientific).  Reverse transcription of RNA into 
cDNA was synthesized from 800ng- 1μg of total RNA using the iScript cDNA synthesis 
kit (Bio-Rad, CA, USA) according to the manufacturers’ instructions. Quantitative 
reverse transcriptase-polymerase chain reaction (RT-PCR) was initiated by iTaq 
Universal SYBR Green Supermix (Bio-Rad, CA, USA) according to the manufacturer’s 
instructions. The PCR reactions (20µl) were performed in a CFX-96 Bio-Rad C-1000 
thermal cycler (Bio-Rad Laboratories, Hercules, CA). Analysis of the data was completed 
with Bio-Rad CFX manager software version 2.1 (Bio-Rad Laboratories). All the PCR 
measurements were performed in triplicate. Following amplification, the specificity of 
the reaction was confirmed by cDNA melting curve analysis. Relative quantitation of the 
gene products was determined using the comparative CT method with data normalized to 
β-actin mRNA and calibrated to the average ΔCT of untreated controls (Lai et al., 2009). 
RNA primers used for the PCR analysis were designed using Primer3 software and 
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purchased from Integrated DNA Technologies, Inc. (Coralville, IA). The sequences are 
listed in Table 3.1. 
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Table 3.1. Oligonucleotide primers used for Real-Time PCR 
Primers  Sequences 
   
IDO1 Forward 5'-GCACCAGAGGAGCAGACTAC-3' 
 Reverse 5'-GATTTGGCAGAGCAAAGCCC-3' 
   
TGF-β1 Forward 5'-GAGCCTGAGGCCGACTACTA-3' 
 Reverse 5'-GGGTTCAGGTACCGCTTCTC-3' 
Activin-βA Forward 5'-GGAGGGCAGAAATGAATGAA-3' 
 Reverse 5'-CCTTGGAAATCTCGAAGTGC-3' 
ITGB8 Forward 5-'CGAGGAGTTTGTGTTTGTGG-3' 
 Reverse 5'-CATCTGCCTGCTTCACACTC-3' 
Nodal Forward 5'-AGACATCATCCGCAGCCTAC-3' 
 Reverse 5'-CCATGCCAGATCCTCTTGTT-3' 
β-Actin Forward 5'-GCATTGCTTTCGTGTAAATTATGT-3' 
 Reverse 5'-ACCAAAAGCCTTCATACATCTCA-3' 
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Immunoblotting 
DCs were harvested by centrifugation (540g, 4oC for 5mins) using an Allegra X-15R 
centrifuge (Beckman Coulter) equipped with a SX4750A rotor. The cells were washed 
with cold PBS and the pellets lysed with 150µl 1 X SDS (sodium dodecyl sulfate-
polyacrylamide) sample buffer (Tris.Cl 50mM pH 6.8, 2% SDS, 10% glycerol). The cell 
membranes were further disrupted by sonication for 10 secs (3 x) with a Sonic 60 
Dismembrator (Fisher Scientific, Sunnyvale, CA) at 10W. The cell extract was boiled at 
99oC for 5mins and centrifuged at 14,000 RPM for 30secs. The supernatants were 
transferred to fresh micro-centrifuge tubes and beta-mercaptoethanol (BME; 0.74M) was 
added after determining protein concentration using DC Protein Assay (Bio-Rad), before 
storage at -20oC. Approximately 40µg of the total protein from the DC cell extracts was 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a 10% gel. The separated proteins were transferred, from the gel, to polyvinylidene 
difluoride (PVDF) (0.45µm; EMD Millipore) or nitrocellulose membranes (0.45µm; 
Thermo Scientific), and probed with antibodies against, phosphorylated Smad 2/3 
(1:1000; Cell Signaling), Smad2/3 (1:1000; EMD Millipore) IDO1 (1:2500; Abcam), and 
beta-actin (dilution 1:1000; Cell Signaling) was used as a loading control. The primary 
antibodies were probed by horseradish peroxidase-conjugated anti-rabbit (1:1000; Cell 
Signaling) or anti-mouse IgG (1:2000-1:5000; Sigma). The membranes were exposed to 
X-ray film (CL-XPosure, Thermo-Scientific) and protein expression was detected 
between CTB-INS treated and untreated conditions and expression intensity was 
analyzed and quantified by densitometry, using Image J software v. 1.48h. (Image J, 
NIH), between CTB-INS treated and untreated conditions. 
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Statistical Analysis 
The data was analyzed for statistical significance using the GraphPad prism 5 
(GraphPad Software, San Diego, CA). Welch’s t-Test (unpaired t-Test with Welch’s 
correction) was used for each pairwise comparison and one-way analysis of variance 
(ANOVA) was used for multiple group comparisons. 
 
Results 
Vaccination of Human moDCs with CTB-INS Induces Integrin αvβ8, TGF-β1 and 
activin-A mRNA Synthesis 
TGF-β1 was shown to induce IDO1 expression in murine DC subsets (Belladonna et 
al., 2008; Pallotta et al., 2014; Pallotta et al., 2011). We therefore assessed the potential 
for CTB-INS to activate TGF-β1 gene transcription and select members of the TGF-β1 
superfamily of cytokines known to utilize similar signaling pattern, specifically activin-A 
and NODAL.  Treatment of healthy subject moDCs with CTB-INS resulted in 
significantly increased TGF-β1 mRNA expression, although mRNA levels declined 6 
hours after vaccine addition (Fig. 3.2A). Activin-A expression increased significantly 
reaching ~20-fold increase in expression at 6 hours after CTB-INS addition (Fig. 3.2B). 
IDO1 expression increased significantly from the first hour of culture and IDO1 
expression was substantially amplified to more than 120-fold after 6hours (Fig. 3.2D), 
confirming earlier published data of CTB-INS induction of IDO biosynthesis(Mbongue et 
al., 2015). However, NODAL gene expression after CTB-INS treatment of moDCs did 
not increase significantly from basal levels (Fig. 3.2C). Integrin αvβ8 was shown to be 
critical for TGFβ1 activation in maintaining immune homeostasis (Aluwihare et al., 
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2009a; Travis et al., 2007b). Interestingly, CTB-INS upregulated integrin αvβ8 
expression by more than 30-fold at 6 hours of moDC treatment (Fig. 3.2E).  
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Figure 3.2. TGF-β1 superfamily and IDO1 mRNA synthesis in CTB-INS vaccinated 
moDCs. Healthy human moDCs were untreated (control), or treated with 5µg/ml of CTB-
INS fusion protein. DC samples were harvested at 1hr, 3hr and 6hr after the addition of 
CTB-INS protein. The DCs were lysed and total RNA extracted for mRNA quantification 
normalized to β-Actin mRNA by real-time PCR. Fold change in the levels of: (A) TGF-β1 
mRNA, (B) activin-βA subunit mRNA, (C) NODAL mRNA, (D) IDO1 and (E) Integrin 
β8 subunit mRNA, were normalized and presented relative to mRNA expression in 
untreated cells. Data for each gene represents the mean ± SD of four to six independent 
experiments. p values of treatment vs control was obtained using Welch’s t-Test; ns, not 
significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; p values on the bars were 
obtained by ordinary one-way ANOVA.  
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CTB-INS Induction of IDO1 Expression in Human moDCs is Independent of TGF-β1 
or Activin-A Cytokine Expression 
Next, we determined whether CTB-INS stimulated TGF-β cytokine production in 
order to induce IDO1 biosynthesis, through autocrine/paracrine signaling in human 
moDCs. To evaluate the effect of endogenous TGF-β induction by CTB-INS on IDO1 
expression, we cultured DCs with pan-TGF-β neutralizing antibody in the presence of 
CTB-INS.  IDO1 biosynthesis was not significantly reduced by antibody binding of 
endogenous TGF-β (Fig. 3.3A).   
TGF-β propagates intracellular signals by inducing the phosphorylation of Smad2 
and Smad3, which is the canonical signaling pathway for the ligand (Massagué, 2012). 
Assessment of the phosphorylation of Smad2/3 following TGF-β neutralization showed 
that deprivation of endogenous TGF-β did not inhibit phosphorylation of Smad2/3 in the 
CTB-INS treated DCs (Fig. 3.3B). This result suggests that CTB-INS stimulates Smad2/3 
signaling independently of endogenous TGF-β1 levels. To confirm the validity of this 
experimental observation, the TGF-β neutralizing antibody was shown to effectively 
inhibit Smad2/3 phosphorylation in the presence of TGF-β1 stimulation (Fig. 3.3A, 
Inset). 
Previously, TGF-β was shown to induce IDO expression in specific murine DC 
subsets (Belladonna et al., 2008; Pallotta et al., 2014; Pallotta et al., 2011). Based on 
these results, we evaluated the effect of exogenous TGF-β on human moDCs. Immature 
DC cultures were treated with increasing amounts of biologically active TGF-β1 and 
analyzed by Immunoblotting for detection of IDO1 expression. However, no IDO1 
biosynthesis was detected in the TGF-β treated DCs (Fig. 3.3C), while, CTB-INS treated 
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DCs expressed high levels of IDO1 protein (Fig. 3.3C). The biological activity of the 
exogenous TGF-β1 was determined by measurement of Smad2/3 phosphorylation after 
TGF-β1 treatment. Phosphorylation of Smad2/3 increased in a dose dependent manner in 
response to exogenous TGF-β1 (Fig. 3.3D), showing that Smad2/3 signaling occurred in 
the presence of exogenous TGF-β1, although IDO1 expression was not induced. 
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Figure 3.3.  Effects of TGF-β on IDO1 biosynthesis in human moDCs. Panel (A) 
Immunoblot showing IDO1 expression of human moDCs, pre-incubated for 60 mins in the 
presence or absence of anti-TGF-β or isotype control prior to treatment with CTB-INS 
fusion protein or vehicle (PBS), for a period of 24 hours. β-actin was included as a control 
for sample loading. To the right of panel A is a graph showing the corresponding 
densitometry data (mean ± SD from three experiments; ns, not significant, obtained by 
Welch’s t-Test for CTB-INS only vs CTB-INS+Anti-TGF-β) normalized to β-Actin, 
indicating IDO1 protein expression relative to normalized expression in the untreated 
cultures (i.e. cells exposed to vehicle only). Panel A graph Inset, confirms phospho-
Smad2/3 biosynthesis in moDCs is stimulated with TGF-β (20ng/ml) and neutralized with 
anti-TGF-β antibody (20µg/ml) (B) A representative immunoblot of human moDCs pre-
incubated with the anti-TGF-β neutralizing antibody and stimulated with CTB-INS for 30 
mins prior to lysis and assessment of phosphorylated-Smad2/3 levels. Anti-Smad2/3 and 
anti-beta-actin antibody were used as loading controls. (C) Immunoblot of human 
peripheral blood moDCs treated with CTB-INS or increasing concentrations (20-
100ng/ml) of TGF-β1 for 24 hours prior to assessment of IDO1 protein expression levels. 
(D) Immunoblot of phosphorylated Smad2/3 obtained from human moDCs treated for 
30mins with increasing concentration of TGF-β for 30mins prior to total cell extraction. β-
Actin was included as control for sample loading. Representative blots were taken from at 
least two independent experiments.  
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Activin-A is a member of the TGF-β superfamily that also signals via Smad2/3 
proteins (Massagué, 2012; Xia and Schneyer, 2009).  Considering that activin-A mRNA 
was upregulated (Fig. 3.2B) and phosphorylation of Smad 2/3 was increased in CTB-INS 
vaccinated human moDCs despite TGF-β neutralization (Fig. 3.3B), we investigated the 
possibility that CTB-INS stimulated endogenous production of activin-A resulting in the 
induction of IDO biosynthesis in human moDCs.  Therefore, we repeated the 
experimental procedure by blocking endogenous activin-A biosynthesis with increasing 
concentrations of follistatin, a natural antagonist of activin-A that binds activin with high 
affinity (Hardy et al., 2015). Human moDC cultures were incubated +/- CTB-INS in the 
presence or absence of follistatin for 24 hours prior to assessment of IDO1 expression by 
immunoblot analysis. Follistatin neutralization of activin-A did not significantly suppress 
vaccine induction of IDO1 expression (Fig. 3.4A). In addition, cytokine neutralization of 
CTB-INS treated DCs with both TGF-β neutralizing antibody and follistatin, did not 
significantly decrease IDO1 protein expression (Fig 3.4A +Anti-TGF-β lane). 
Based on earlier reports that, neutralization of activin by high concentrations 
(400ng/ml) of follistatin  did not abrogate levels of activin-A stimulated in moDCs after 6 
hours(Robson et al., 2007), we hypothesized that early biosynthesis of activin-A 
following CTB-INS stimulation of the moDCs might be responsible for induction of 
IDO1 expression. To test this hypothesis, we measured IDO1 mRNA by real-time PCR in 
vaccinated DC cultures incubated with or without follistatin, before and at 6 hours of 
culture. However, no significance difference in IDO1 expression was detected between 
cell cultures treated with or without follistatin (Fig. 3.4B), substantiating our previous 
observation that while activin-A is stimulated in CTB-INS treated DCs, the cytokine had 
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no effect on enhancement of vaccine stimulated IDO1 biosynthesis.  To confirm these 
findings moDCs were treated with increasing concentrations of exogenous activin-A and 
IDO1 protein expression was assessed by immunoblot analysis. No IDO expression was 
detected (Fig. 3.4C). These novel findings suggest that TGF-β and activin-A cytokines 
exert no significant effect on the induction of IDO1 in human moDCs. Interestingly, as 
shown with TGF-β1, exogenous activin-A effected Smad2/3 signaling, as detected by 
increased phosphorylation of Smad2/3 after 30mins treatment with activin-A (Fig. 3.4D).  
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Figure 3.4. Effects of activin-A on the induction of IDO1 in moDCs. Panel (A) 
Immunoblot of IDO1 levels in human moDCs incubated with vehicle (PBS) or CTB-INS 
fusion protein incubated for 24hours in the presence of increasing concentrations (100-
400ng/ml) of the activin-A inhibitor, follistatin, alone or follistatin (400ng/ml) plus pan-
TGF-β neutralizing antibody (20µg/ml). β-actin was used as a loading control. 
Densitometry data (mean ± SD) indicating IDO1 protein expression in the samples from 
two independent experiments, normalized to β-Actin, is shown on the right; expression in 
the respective samples is relative to normalized expression in the untreated cultures (i.e. 
cells exposed to vehicle only). (B) Graphic representation of normalized fold change of 
IDO1 mRNA, relative to mRNA expression in control cells, of human moDCs treated with 
vehicle (control) or with CTB-INS (5µg/ml) at 1hr, 3hr and 6hr time points in the absence 
or presence of follistatin (400ng/ml). The moDCs were harvested and lysed and RNA was 
extracted for mRNA quantification by real-time PCR, relative to β-Actin mRNA. Data 
represents mean ± SD of three independent experiments. p values of paired comparison 
was obtained using Welch’s t-Test; ns, not significant. (C) Immunoblot of IDO1 expression 
in moDCs treated with CTB-INS or increasing concentrations (10-100ng/ml) of activin-A 
for 24 hours. (D) Immunoblot of phosphorylated Smad2/3 in human moDCs untreated or 
treated with increasing concentration of activin-A for 30mins, after which total cell extracts 
were obtained for analysis. β-Actin was used as loading control. Representative blots are 
of at least two independent experiments.  
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CTB-INS Vaccine Activates Smad2/3-Independent Kinase Signaling to Stimulate 
IDO1 Biosynthesis in Human moDCs 
Previous studies have demonstrated TGF-β-independent activation of Smad2/3 
signaling pathway in rat vascular and renal cells (Rodríguez-Vita et al., 2005; Yang et al., 
2009).  Therefore, we investigated whether CTB-INS activated Smad2/3 signaling to 
induce IDO1 expression independently of TGF-β. To accomplish this goal, we examined 
the effect of a bioactive small molecule inhibitor of TGF-β signaling, RepSox, on CTB-
INS induction of IDO1 expression in human moDCs. RepSox blocks TGF-β1 signaling 
by binding to and inhibiting phosphorylation of the TGF-β type I serine/threonine kinase 
receptor, ALK5/TβRI, thereby blocking phosphorylation of Smad2/3 (Gellibert et al., 
2004; Ichida et al., 2009). Human moDC cultures were treated with CTB-INS in the 
presence or absence of the inhibitor. Western blot analysis of IDO1 protein expression 
showed that IDO1 biosynthesis was significantly decreased in the presence of RepSox 
(Fig. 3.5A). While RepSox (25µM) inhibited phosphorylation of Smad2/3 in the DCs 
(Fig. 3.5B), treatment of DCs with lower concentrations (12.5µM) of RepSox, did not 
decrease IDO1 protein expression (Fig. 3.5C), suggesting IDO1 suppression by RepSox 
is concentration dependent.  
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Figure 3.5. Arrest of IDO1 protein synthesis in CTB-INS vaccinated moDCs by the kinase 
inhibitor RepSox. Panel (A) A representative immunoblot analysis of IDO protein 
synthesis in moDCs incubated with RepSox (25µM) or DMSO (vehicle) for 1hr prior to 
24hrs incubation with CTB-INS (5µg/ml). The graph at the right represents pooled 
densitometry data from 3 independent experiments (mean ± SD; **p < 0.01 obtained by 
Welch’s t-Test for CTB-INS only vs CTB-INS + RepSox DCs; ****p < 0.0001 obtained 
by ordinary one-way ANOVA comparing relative IDO expression between groups), 
normalized to beta-Actin. IDO1 expression in vaccinated moDCs is relative to normalized 
IDO1 expression in untreated cells. (B) Representative immunoblot of phospho-Smad2/3 
biosynthesis in moDCs incubated with RepSox (25µM) or DMSO (vehicle) for 1hr 
followed by treatment with CTB-INS for 30mins, after which total cell extracts were 
subjected to immunoblot analysis. Anti-Smad2/3 and anti-beta-actin antibody were used 
as loading control. (C) Representative Immunoblot analysis of IDO1 expression in moDCs 
treated with RepSox (12.5µM) followed by treatment with CTB-INS (5µg/ml). 
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DCs were then treated with the small molecule serine/threonine kinase inhibitor, SB-
431542 (10µM), known to selectively block the type I receptor kinases of TGF-β, activin 
and NODAL, resulting in the inhibition of Smad2/3 signaling (Inman et al., 2002). 
Although Smad2/3 signaling was inhibited (Fig. 3.6B), the application of SB-431542 did 
not suppress CTB-INS-stimulation of IDO1 protein synthesis (Fig. 3.6A). Interpretation 
of this data suggests that CTB-INS induces IDO1 protein expression in human moDCs 
independently of the Smad2/3 signaling pathway. 
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Figure 3.6. Effect of TβRI kinase inhibition on IDO1 protein synthesis and Smad2/3 
phosphorylation in CTB-INS induced moDCs. Panel (A) Representative immunoblot of 
IDO1 expression in moDCs after pretreatment with vehicle (DMSO) or the 
serine/threonine kinase specific inhibitor SB-431542 (10µM) for 1 hour, followed by 24 
hour incubation of the moDCs with CTB-INS (5µg/ml). Anti-β-Actin Ab was used as the 
loading control. (B) Immunoblot of phospho-Smad2/3 expression in moDCs pretreated for 
1 hour with DMSO or SB-431542 followed by 30mins incubation with CTB-INS (5µg/ml). 
Immunoblot analysis was conducted for Smad2/3 expression and blots were stripped and 
re-probed with anti-β-Actin Ab as a control for equivalent sample loading. The data 
presented is representative of two independent experiments. 
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Discussion 
Signaling pathways responsible for CTB-INS induction of IDO1 biosynthesis are 
poorly defined in human moDCs.  Therefore, we examined the role of TGF-β 
superfamily members in CTB-INS vaccine upregulation of IDO1 biosynthesis in human 
DCs.  In this study, we present experimental evidence that CTB-INS stimulation of IDO1 
biosynthesis in human moDCs may occur through signaling pathways that are potentially 
dependent on the activation of kinases, but independent of members of TGF-β 
superfamily kinase receptors.    
Our experimental data indicates that CTB-INS fusion protein vaccine upregulates 
TGF-β1 and activin-A mRNAs in human moDCs, and stimulates TGF-β signaling, 
further confirmed by detection of CTB-INS stimulation of Smad2/3 phosphorylation. 
Activin-A, a member of the TGF-β superfamily, regulates human moDC and modulates 
DC proinflammatory cytokine profile (Robson et al., 2007). Similarly, TGF-β signaling is 
a critical factor that contributes to maintaining immune cell homeostasis. Absence of 
TGF-β1 signaling in DCs leads to multi-organ autoimmune inflammation or autoimmune 
conditions (Boomershine et al., 2009; Ramalingam et al., 2012). In addition, TGF-β1 
signaling is required for induction of tolerogenic DCs (Lan et al., 2012).  It is plausible 
that the upregulation of these immunoregulatory factors are additional mechanisms by 
which CTB-INS modulates moDC towards a tolerogenic phenotype as previously 
demonstrated by our laboratory(Odumosu et al., 2011b).     
Based on the  observation that CTB-INS stimulated an increase in TGF-β or 
activin-A production, we speculated that autocrine/paracrine signaling of TGF-β or 
activin-A could be directly or indirectly involved in the upregulation of IDO1 
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biosynthesis, as previously suggested (Belladonna et al., 2008). However, our 
experimental data demonstrates that IDO1 biosynthesis in CTB-INS treated human 
moDCs is independent of endogenous TGF-β or activin-A. In experiments involving 
murine CD8-, plasmacytoid DCs (pDCs), and bone-marrow-derived DCs, the addition of 
biologically active TGF-β induced IDO biosynthesis and converted or maintained the 
DCs in a tolerogenic state (Belladonna et al., 2008; Pallotta et al., 2014; Pallotta et al., 
2011; Song et al., 2014). However, in our experiments with human moDCs, the 
exogenous addition of bioactive TGF-β or activin-A cytokines did not induce IDO1 
biosynthesis, thereby, further excluding potential, non-Smad TGF-β/activin-A signaling 
in the induction of IDO1 synthesis in human moDCs (Derynck and Zhang, 2003; Mu et 
al., 2012). While the molecular details are unknown, our data suggests TGF-β induction 
of IDO in immune cells may be species-specific, further confirming the findings of others 
that differences in immunological responses may occur between mammalian species 
(Cheng et al., 2015; Schmidt et al., 2010). Otherwise, the differences between our results 
and others (Belladonna et al., 2008; Pallotta et al., 2014; Pallotta et al., 2011; Song et al., 
2014), may be a function of differences in DC ontogeny. To our knowledge this is the 
first time TGF-β family cytokine involvement in the induction of IDO1 biosynthesis in 
human moDCs has been documented and provides insight into signaling pathways 
involved in the induction of IDO1-expressing tolerogenic human moDCs, with the view 
of potential therapeutic applications. Further, we have previously demonstrated that CTB-
INS activates tumor necrosis factor (TNF) receptor members in the modulation of IDO1 
induction (Kim et al., 2016). However, additional research is required to clarify the 
mechanism of chimeric vaccine induction of IDO1 for immunological tolerance. 
 99 
The serine/threonine kinase specific inhibitor, SB-431542 (Inman et al., 2002), 
did not block CTB-INS induction of IDO1 biosynthesis in moDCs (Fig. 3.6A), 
reinforcing the idea that CTB-INS induction of IDO1 biosynthesis in human moDCs may 
be independent of Smad2/3 signaling. Interestingly, data from the use of the kinase 
inhibitor, RepSox, is consistent with previous studies showing RepSox may inhibit the 
activity of serine/threonine kinases of other signaling pathways at concentrations greater 
than 16µM (Gellibert et al., 2004). Although RepSox blocked phosphorylation of the 
TGF-β type I kinase receptor, ALK5/TβRI, the application of RepSox at the 
concentration of 25µM may have inhibited kinase activity integral to other signaling 
mechanisms including the non-canonical NF-κB signaling pathway shown to be activated 
by CTB-INS in inducing IDO1 biosynthesis and activity in human moDCs (Kim et al., 
2016). Thus, the mechanism underlying RepSox suppression of CTB-INS-mediated 
IDO1 biosynthesis may require further clarification. 
CTB-INS stimulation of integrin αvβ8 expression reported in this study may 
represent a novel mechanism for CTB-INS induction of tolerance in human moDC via 
the activation of TGF-β1. The activation of latent TGF-β1 is critical for its 
immunoregulatory functions which include inhibition of DC-mediated immune responses 
(Hammer and Ma, 2013; Worthington et al., 2012). TGFβ controls and limits the 
differentiation of DCs at autoimmune-inflammatory sites and TGFβ–secreting DCs 
stimulate Treg proliferation (Ghiringhelli et al., 2005; Speck et al., 2014). In addition, 
TGFβ skews Th1/Th2 balance towards a Th2 profile (Becker et al., 2006; Maeda and 
Shiraishi, 1996). Studies have indicated a role for integrin αvβ8 in the suppression of 
autoimmunity by activation of TGFβ1. Mice with gene deletions of integrin αvβ8 or with 
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DCs deficient in integrin αvβ8 expression, developed immune dysfunction due to failure 
to activate TGFβ1 (Aluwihare et al., 2009a; Travis et al., 2007b). Further, specific 
intestinal subsets of murine DCs required the expression of integrin αvβ8 to activate 
TGF-β1 and generate regulatory T cells for the induction of tolerance to intestinal 
antigens (Païdassi et al., 2011; Worthington et al., 2011). It should be noted that in earlier 
reports of CTB-INS suppression of diabetes insulitis in NOD mice, the CTB-autoantigen 
fusion proteins were orally administered to the mice (Carter et al., 2006b). It is plausible 
that the mechanism of immune suppression in these early studies involved tolerance 
induction of intestinal DCs by integrin αvβ8 upregulation. The additional observation by 
others of integrin αvβ8 expression and requirement in immunosuppressive functions of 
Tregs, indicates the imperative for further investigation of the significance of integrin 
αvβ8 upregulation reported here for the first time in human moDCs (Worthington et al., 
2015).  
In conclusion, the present study identifies novel tolerogenic functions of CTB-
INS fusion protein vaccine. CTB-INS stimulates both TGF-β and activin-A biosynthesis 
as well as Smad2/3 phosphorylation and induces integrin αvβ8 expression in human DCs. 
Although our data demonstrates that CTB-INS upregulation of TGF-β superfamily 
proteins is not related to the induction of IDO1 biosynthesis in human moDCs, it is likely 
that CTB-INS fusion protein activates multiple mechanisms for tolerizing DCs. Taken 
together, these observations suggest CTB-INS may employ TGF-β synthesis and 
activation in the induction of tolerance in human moDCs. Experiments to further validate 
the present experimental findings and to understand the mechanisms involved will help to 
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establish the vaccine function in moDCs and will provide a basis for determination of 
vaccine efficacy for induction of immunological tolerance in T1D. 
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CHAPTER 4 
CHOLERA TOXIN B SUBUNIT-PROINSULIN VACCINE INDUCTION OF 
TGF-BETA IN HUMAN DENDRITIC CELLS 
 
Introduction 
Dendritic cells (DCs) are professional antigen presenting cells that coordinate the 
adaptive immune cells towards an immune response or to mediate immunological 
tolerance by mechanisms such as T cell deletion or anergy, Th2 skewing and induction of 
regulatory T cells (Tregs)(Danese et al., 2008) (Shortman and Naik, 2007). First 
described by Steinman in 1973, DCs are a widely distributed heterogeneous population of 
cells classified by ontogeny, phenotypic characteristics and functional attributes, with 
specialized functions (Liu and Cao, 2015; Steinman and Idoyaga, 2010). DCs modulate 
key immune processes including autoimmunity, which is an immune response 
characterized by failure of tolerance to self-antigens(Benson et al., 2010) . Tolerogenic 
DCs hold promise as potential therapy for autoimmune diseases and can be characterized 
by an immature or semi-immature phenotype demonstrated by expression of low 
costimulatory molecules, high expression of anti-inflammatory cytokines, and decreased 
expression of pro-inflammatory cytokines and induction of hyporesponsive CD4+ T cells 
(Hilkens et al., 2010; Schinnerling et al., 2015; Ten Brinke et al., 2015). Therefore, 
understanding the mechanisms that regulate DC homeostasis is crucial to harnessing their 
therapeutic potentials (Merad and Manz, 2009).   
TGFβ is a pleiotropic cytokine affecting numerous cellular and immune 
processes, especially playing a central role in T cell development, homeostasis, tolerance 
and differentiation (Guerder et al., 2013). The immunosuppressive action of TGFβ on 
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dendritic cells can promote or inhibit DC-mediated immune responses (Worthington et 
al., 2012). TGFβ controls and limits the differentiation of DCs at autoimmune-
inflammatory sites (Speck et al., 2014). TGF-β was shown to modulate homeostasis of 
DCs of the epidermis, also called Langerhans cells(LC) by suppression of maturation 
states of the LC (Kel et al., 2010). TβR1-deficient LCs significantly upregulated 
expression of CD86 and CCR7 compared to the wild-type, indicating switch in 
phenotype from immature to mature DCs and migratory potential of the DCs were also 
enhanced(Kel et al., 2010). Further, TGF-β-conditioned bone marrow-derived DCs 
(BMDCs) co-transplanted with islets, prolonged their survival and decreased T-cell 
infiltration of the graft islet (Thomas et al., 2013).The TGF-β-exposed DCs displayed low 
costimulatory molecule (CD80 and CD86) expression and reduced pro-inflammatory 
cytokine (IL-12 p70, IL-6, Il-1β, TNF-α) profile, maintaining IL-10 production, and 
poorly activating antigen-specific T cells cells (Thomas et al., 2013). 
TGF-β is a tightly regulated cytokine that is secreted and maintained as an 
inactive precursor that requires activation to become functional (Hammer and Ma, 2013; 
Mu et al., 2002). TGF-β is synthesized as a homodimeric pro-protein consisting of the 
active TGF-β1 covalently linked to the latency associated peptide (LAP). After enzymatic 
cleavage in the Golgi, the LAP remains attached to the mature TGF-β1 by non-covalent 
bonds, and hinders the binding of the active TGF-β1 to its cognate receptors (Li et al., 
2006b; Wipff and Hinz, 2008; Worthington et al., 2012). Integrin αv family recognize 
specific arginine-glycine-aspartate RGD sequences present on LAP by which they bind to 
the latent TGF-β complex and liberate the active TGF-β to interact with its receptors 
(Song et al., 2016). Integrin αvβ8 has been well characterized to be critical for TGF-β1 
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activation and in maintaining immune homeostasis; mice whose leucocytes are deficient 
in integrin αvβ8 develop a wasting inflammatory disorder (Aluwihare et al., 2009b; Mu et 
al., 2002; Travis et al., 2007b). 
Type 1 diabetes mellitus (T1D) is a tissue-specific autoimmune disease where 
autoreactive T cells mediate progressive destruction of the islet cells of the pancreas 
resulting in insulin deficiency that can be fatal in the absence of therapy (Segovia-
Gamboa et al., 2014). Tolerogenic DCs have been explored as therapy for autoimmune 
diseases and have been demonstrated to reverse diabetes in the non-obese diabetic (NOD) 
mice which is the murine model for T1D (Segovia-Gamboa et al., 2014). Previous 
experiments in our laboratory have shown that a chimeric fusion protein composed of the 
cholera toxin B subunit conjugate to the diabetes autoantigen proinsulin (CTB-INS) can 
suppress the activation of dendritic cells through suppression of DC costimulatory 
molecules, CD86 and CD80, and pro-inflammatory cytokines, and induction of an anti-
inflammatory cytokine profile; a response that is significant in preventing the onset of 
type 1 diabetes (T1D) (Odumosu et al., 2011b).  Recently our laboratory showed that 
CTB-INS upregulates gene expression of integrin αvβ8, TGF-β and increased Smad 2/3 
signaling (Chapter 3). In this preliminary study we investigate the expression of integrin 
αvβ8 and TGF-β protein expression as a mechanism for CTB-INS induction of tolerance 
in human moDCs. 
 
Materials and Methods 
Monocyte Isolation and DC Culture 
Experiments on peripheral blood mononuclear cells (PBMCs) were performed ex-
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vivo, with aphaeresis blood provided by the Life Stream Blood Bank (San Bernardino, 
CA) according to Loma Linda University IRB requirements. Blood donor information 
was anonymized before initiation of the study. Human monocytes were isolated from 
peripheral blood, after red blood cell lysis, using LS separation columns and anti-CD14 
magnetic MicroBeads (Miltenyi Biotec) as previously described (Mbongue et al., 2015) 
and maintained in culture at a density of 5 x 105 to 1 x 106 cells/ml. Immature DCs were 
differentiated from CD14 positive monocytes by incubation for 6 days in RPMI 1640 
medium (Hyclone, GE Healthcare Life Sciences) containing 10% FBS and supplemented 
with human GM-CSF (50ng/ml) and human IL-4 (10ng/ml) (Miltenyi Biotec).  Half the 
medium was replaced with fresh medium every 2 days being careful not to dislodge the 
cells from the substrate. 
 
Synthesis and Isolation of CTB-INS Fusion Protein 
CTB-INS fusion protein was synthesized in the E. coli expression vector, strain 
BL-21 (DE3) pLysS (Invitrogen, Carlsbad, CA ) and purified as previously described 
(Mbongue et al., 2015; Odumosu et al., 2011b). Briefly, CTB-INS protein synthesis in 
the bacterial culture was stimulated with 2.0mM isopropyl β-D-1-thiogalacto-pyranoside 
(IPTG), (Sigma Chemical Co. St Louis, Mo) at 3 hours of culture. Bacteria cell culture 
was harvested at density of 0.2-0.4 O.D.600, and the his-tagged CTB-INS protein was 
isolated from the bacterial cell homogenate using Maxwell Model 16 robotic protein 
purification system (Promega, Inc.) according to the manufacturer’s instructions. The 
elution buffer was removed by dialysis at 4°C in phosphate buffered saline (PBS) and the 
purity of the isolated protein was determined by polyacrylamide gel electrophoretic 
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mobility analysis followed by immunoblotting (Western) with anti-Cholera Toxin as the 
primary antibody (Sigma, Inc). 
 
Dendritic Cell Treatments 
The differentiated human moDCs (assessed by observation of dendrite formation 
using phase contrast microscopy) were incubated with 5µg/ml of CTB-INS protein or 
vaccine vehicle (control) for 1hour, 3hours, and 6hours time points, or at separate 
experiments, for 24hours.  
 
TGF-β1 ELISA 
The TGF-β1 cytokine concentration in DC culture supernatants was assessed 
using the Human/Mouse TGF-β1 ELISA Ready-Set-Go kit (2nd generation) (eBioscience) 
according to the manufacturer’s protocol. Culture supernatants of human moDC cultures 
obtained from untreated DCs and DCs treated with CTB-INS for 1, 3, 6, and 24 hours 
were collected and immediately stored at -80°C until further analysis. A 100µl volume of 
the supernatants of each sample, was analyzed by the ELISA in duplicates. Active TGF-
β1 induced by CTB-INS was assessed by assay of the free TGF-β1 present in the cell 
culture supernatants. Total TGF-β1 was obtained by acid activation of cell culture 
supernatants to release TGF-β1 to the immunoreactive form. Briefly, samples were 
activated by 1N HCl for 10 minutes and neutralized by 1N NaOH as directed by 
manufacturer of ELISA kit. Acidified samples were diluted three fold with manufacturer 
dilution buffer before assay. Controls were run to determine baseline concentrations of 
TGF-β1 present in culture media. 
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Flow Cytometry 
Adherent and suspended DC were harvested from treated and untreated cell 
cultures, washed with PBS and labelled with fluorescent antibodies conjugated to DC cell 
surface targets. Antibodies and reagents used were anti-human CD11c PE, HLA-DR 
PerCP (Becton Dickinson), CD14-FITC (Biolegend), Human integrin β8-APC (R and D 
Systems), Fixable Viability Dye eFluor 450 (eBioscience). Samples were analyzed using 
Miltenyi MACSQuant flow cytometer (Miltenyi Biotec), and the data analyzed using 
FlowJo software (Tree Star, Ashland, OR). DCs were gated by Forward Scatter Area and 
Side Scatter Area (FSC-A/SSC-A), and cells with CD14low and CD11chi phenotype were 
gated as DCs. 
 
Statistical Analysis 
Data analysis was performed using GraphPad prism 5 (GraphPad Software, San 
Diego, CA). Welch’s t-Test (unpaired t-Test with Welch’s correction) was used for each 
pairwise comparison and one-way analysis of variance (ANOVA) was used for multiple 
group comparisons. 
 
Results 
CTB-INS Induced Increased Expression of Active TGF-Β1 in Vaccinated DCs 
We have examined the effect of CTB-INS on increased biosynthesis of TGF-β1 
mRNA in moDCs (Chapter 3). To better clarify the mechanism by which CTB-INS 
induced tolerance, preliminary study for TGF-β1 cytokine expression was conducted. 
Active TGF-β1 expression increased as analyzed by ELISA, however there was great 
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variability between subjects assessed and increase in active TGF-β1 was not significant 
(Fig. 4.1A). The increase in active TGF-β1 was highest at 3 hours of CTB-INS treatment 
and correlated with TGF-β1 mRNA biosynthesis in response to CTB-INS (Chapter 3). 
Total TGF-β1 did not vary much between treated and untreated moDCs, due to variability 
in the samples, as observed with assay of active TGF-β1 (Fig. 4.1B).  
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Figure 4.1. TGF-β1 cytokine expression in CTB-INS treated human moDCs. Human 
moDCs were cultured and treated with vaccine vehicle (dialysis buffer; CTL) or 5µg/ml of 
CTB-INS for 1hour, 3hours, 6hours, and 24hours. Thereafter, supernatants of cell cultures 
were obtained for ELISA quantification of TGF-β1 cytokine expression. Panel (A) graph 
of active TGF-β1 release in 1, 3, 6hr of CTB-INS time course treatment with cytokine 
expression at 24hr on right of panel. Panel (B) is total TGF-β1 in time course and 24hr 
treatments. Data are presented as mean ± SD from 3 independent experiments. 
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Furthermore, following increased gene expression of the known TGF-β1 
activator, integrin αvβ8 (Chapter 3), CTB-INS treated moDCs were recovered after 
24hours and labelled for cell surface analysis of integrin αvβ8 expression by flow 
cytometry. Integrin αvβ8 was increased in CTB-INS treated moDCs versus untreated 
moDCs (Fig. 4.2A and B).  
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Figure 4.2. Integrin αvβ8 (ITGB8) expression in moDCs. Human moDCs were treated 
with 5µg/ml CTB-INS fusion protein vaccine for 24hrs and analyzed by flow cytometry to 
determine expression of integrin αvβ8. Untreated cells were used as control experiment. 
Data of mean fluorescence intensity (MFI) is represented here for two experiments. (A) 
Histogram overlay depicts expression values of integrin αvβ8 in moDCs with and without 
treatment of CTB-INS. (B) The graph compares the MFI of integrin expression in the 
treated DCs with the untreated moDCs.     
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Discussion 
This chapter documents preliminary studies on the effect of CTB-INS fusion 
protein on TGF-β1 activation. We observed that CTB-INS upregulates active TGF-β1 
expression. TGF-β1 activation is crucial for its biological functions, therefore increase of 
active TGF-β1 expression may be more significant than total or latent TGF-β1 production 
as observed in the present study (Hasegawa et al., 2004). Although these preliminary 
indications of increased active TGF-β1 were not statistically significant, an increase in 
the number of subjects sampled may increase the power of the study and yield more 
replicable data. Previous studies have observed the challenge of measuring TGF-β1 
bioactivity, as only a few cells are able to secrete significant amounts of measurable 
active TGF-β1 in response to appropriate treatments (Glick et al., 1989; Mazzieri et al., 
2000). The absence of abundant active TGF-β1 in the cell culture may not be indicative 
of lack of TGF-β1 activation, but may be due to either TGF-β1 activation occurring on 
the cell surface as a result of TGF-β1 binding to transmembrane cell surface proteins 
(Dennis and Rifkin, 1991; Mazzieri et al., 2000; Munger et al., 1999b), or due to active 
TGF-β1 removal  from the cell culture solution as it binds to its cognate receptors, 
allowing only minute release of active TGF-β1 to the culture media (Mazzieri et al., 
2000).The use of more sensitive assays like the Mink lung epithelial cells luciferase assay 
(Mazzieri et al., 2000), may yield more productive measurement of bioactive TGF-β1, 
than analysis by ELISA. 
The analysis of integrin αvβ8 cell surface protein did not yield dramatic levels of 
expression in CTB-INS treated moDCs. Increasing sample size by repeating the 
experiments will be necessary to establish the validity of these preliminary findings. One 
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reason for the lack of statistically significant increase of Integrin αvβ8 during flow-
cytometric analysis in CTB-INS treated DCs may be related to the lack of ample amount 
of active TGF-β1 in the DC culture stated above: LAP of latent TGF-β1 is a ligand for 
Integrin αvβ8. The binding of Integrin αvβ8 to LAP of the latent TGF-β1 in DCs may 
have impeded availability of integrin αvβ8 for cell surface analysis by flow cytometry 
(Cambier et al., 2005; Munger et al., 1999a) . 
In conclusion, our preliminary studies suggest a role for TGF-β1 and integrin 
αvβ8 in the mechanism by which CTB-INS exerts tolerogenic functions on human 
moDCs.  Further analysis of CTB-INS induction of integrin αvβ8 on moDC 
immunosuppression, that include CTB-INS suppression of DC costimulatory molecules 
CD80 and CD86 and induction of regulatory T cells (Tregs), will help to assess the 
significance of integrin αvβ8 upregulation and TGF-β1 activation in human moDCs. 
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CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
In this body of work we sought to elucidate the mechanisms by which CTB-INS 
induces tolerogenicity of DCs as a means of evaluating its efficacy for clinical 
applications for therapy in autoimmune diabetes, and to understand the mechanistic 
processes involved in the induction of DC tolerance for broader application in tissue 
specific and systemic autoimmune disease conditions and immunosuppressive 
mechanisms involved in tissue rejection and cancer. 
Chapter 1 discusses therapeutic strategies for autoimmune diseases and highlights 
current findings that indicate the prospects of tolerogenic DCs in the fight against 
immune dysregulation. This review establishes the need to identify key regulators or 
biomarkers of DC tolerogenicity so as to enable the generation and maintenance of 
tolerogenic DCs. Known indicators of DC tolerogenicity are further discussed and studies 
with the immunosuppressive chimeric CTB subunit autoantigen conjugate (CTB-INS) 
fusion protein are introduced. CTB-INS and its various autoantigen fusion proteins may 
induce tolerogenesis along multiple pathways. Previous studies in our laboratory have 
shown that CTB-INS and other CTB conjugated autoantigen fusion proteins can prevent 
and treat diabetes insulitis in the non-obese diabetes (NOD) mice (Carter et al., 2006b), 
prevent costimulatory molecule expression and DC activation of human moDCs 
(Odumosu et al., 2011a; Odumosu et al., 2011b), suppress pro-inflammatory cytokine 
expression, enhance anti-inflammatory cytokine profiles, modulate anti-inflammatory T 
cell morphogenesis (Odumosu et al., 2011b) (Odumosu, et al., unpublished), and induce 
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biosynthesis of the immunoregulatory molecule, IDO1(Mbongue et al., 2015).  Chapter 2 
initiates investigation into the mechanism by which CTB-INS induces IDO biosynthesis 
in human moDCs and demonstrates the involvement  of the non-canonical NF-κB 
pathway in CTB-INS-mediated IDO induction (Kim et al., 2016). TGF-β1 was shown to 
employ activation of the non-canonical NFκB pathway to stimulate IDO biosynthesis in 
murine DCs (Belladonna et al., 2008). Therefore, Chapter 3 documents our investigation 
into CTB-INS tolerogenic mechanisms by examination of the role of TGF-β1 in CTB-
INS-mediated IDO biosynthesis in human moDCs. This chapter shows that CTB-INS 
functions in DCs by upregulating TGF-β1 expression and by stimulation of Smad2/3 
signaling; however, no relationship between CTB-INS-induced TGF-β1 and IDO 
biosynthesis is identified.  Further, identification of CTB-INS induction of 
immunoregulatory proteins activin-A and integrin αvβ8, are documented. Lastly, based 
on the potent immunosuppressive functions of TGF-β1 (Shurin et al., 2013), in Chapter 4 
we continue to investigate the nature of CTB-INS upregulation of TGF-β1 and its 
biological activator, integrin αvβ8. The immunological implications of CTB-INS 
induction of integrin αvβ8 in human moDCs, will require elucidating the role of integrin 
αvβ8 in CTB-INS inhibition of DC costimulatory molecule expression and induction of 
regulatory T cells (Tregs).   
 
Future Directions 
Specific Aim 1 
TGF-β1 is a potent immunosuppressive cytokine but requires activation to exert 
its biological functions (Li et al., 2006b). Integrin αvβ8 integrin is critical for TGF-β1 
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activation and is the only integrin expressed on mice CD4+ T cells and dendritic cells 
(Travis et al., 2007b; Worthington et al., 2012). Recent studies in our laboratory have 
shown that the chimeric fusion protein consisting of the cholera toxin B sub unit 
conjugated to the diabetes autoantigen proinsulin (CTB-INS) induces upregulation of 
αvβ8 integrin biosynthesis. Previous studies in our laboratory have established the 
immunosuppressive function of CTB-INS on human monocyte-derived dendritic cell 
(moDC) activation. Further elucidation of the mechanism of CTB-INS induction of 
tolerance is required for validation of its efficacy and safety for therapy in autoimmune 
diabetes. Our long-term goal is to elucidate the immunoregulatory mechanisms involved 
in CTB-INS fusion protein modulation of human dendritic cell tolerance as an essential 
step in evaluating the vaccine efficacy and safety. The objective of the study proposed 
here is to elucidate the role of integrin αvβ8 on CTB-INS suppression of DC activation 
and for the induction of regulatory T cell (Treg) differentiation. The central hypothesis 
behind the proposed research is that CTB-INS fusion protein suppresses DC activation 
and DC-mediated Treg differentiation via integrin αvβ8 activation of TGFβ1. This 
hypothesis is based on documented studies and on data from this dissertation. First, 
integrin is crucial to TGFβ activation. Mice with a point mutation of the RGD integrin 
binding site to RGE in TGFβ1, exhibited complete phenotypic expression as TGFβ1-null 
mice and died from multi-organ inflammatory disease early in life (Yang et al., 2007). 
Second, integrin αvβ8 is highly expressed in mouse intestinal CD103+ DC subsets and is 
required for the generation of regulatory T cells by the intestinal DCs, for maintaining 
immune homeostasis in the intestine (Païdassi et al., 2011). Also, mice with Integrin αvβ8 
deficient leukocytes develop an age-related wasting and inflammatory disorder (Travis et 
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al., 2007b). Third, CTB-INS induces increased expression and biosynthesis of integrin 
αvβ8 in human moDCs (Fig. 3.1E; Fig. 4.2B). Based on these observations, we will test 
our central hypothesis by the following specific aims: 
 
Aim 1.1: Assess Increased Integrin αvβ8 Expression in moDCs following CTB-INS 
Inoculation 
Our working hypothesis here is that increasing levels of integrin αvβ8 protein 
expression correlates with CTB-INS treatment of moDC culture. This will be achieved by 
repeating earlier experiments measuring the upregulation of surface levels of integrin by 
flow cytometry on the membrane of DCs following vaccine inoculation. We expect to 
detect increased integrin αvβ8 expression on CTB-INS vaccinated DCs assessed by 
comparing integrin αvβ8 expression in CTB-INS treated DCs versus untreated DCs.   
 
Aim 1.2: Determine CTB-INS-mediated Induction of TGFβ1 Activation in moDCs 
by Integrin αvβ8 
The working hypothesis is that CTB-INS stimulates activation of TGFβ1 by an 
integrin αvβ8-dependent mechanism to modulate suppression of moDC activation by 
inhibition of DC costimulatory molecule, CD80 and CD86 expression. We will repeat 
experiments showing quantification of TGFβ1 cytokine expression in CTB-INS treated 
DC cell culture supernatants, so as to increase the sample size, by conducting ELISA or 
Cytometric bead array. We will also measure the bioactivity of TGF-beta in CTB-INS 
treated DCs by mink lung epithelial cells luciferase assay. In addition, we will measure 
TGFβ activity after blocking integrin αvβ8 expression by a monoclonal antibody specific 
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to integrin αvβ8 in CTB-INS treated DC cultures, and assess the expression of DC 
costimulatory molecules by flow cytometry analysis. 
 
Aim 1.3: Characterize CTB-INS Modulation of T cell Differentiation 
The working hypothesis here is that CTB-INS modulates DCs to induce Treg 
differentiation by an integrin αvβ8-dependent mechanism. To test this hypothesis the 
phenotypic and cytokine profiles of T cell populations will be assessed by flow cytometry 
of mixed DC-T cell co-cultivation experiments in the presence or absence of CTB-INS 
and integrin αvβ8 neutralizing antibody.   
 
Specific Aim 2 
Smad2/3 signaling is required for the induction of tolerogenic DCs and is induced 
by members of the TGF-β superfamily ligand (Lan et al., 2012). Earlier studies have 
observed the occurrence of TGF-β-independent activation of Smad2/3 signaling pathway 
in rat vascular and renal cells (Rodríguez-Vita et al., 2005; Yang et al., 2009).  Previous 
studies in our laboratory have established the immunosuppressive function of CTB-INS 
on the activation of human monocyte-derived dendritic cells (moDC). Further elucidation 
of the mechanism of CTB-INS induction of tolerance is required for validation of its 
safety for therapy in autoimmune diabetes. Our long term goal is to elucidate the 
suppressive mechanisms underlying CTB-INS fusion protein modulation of human 
dendritic cell activation as an essential step in evaluating the efficacy and safety of the 
vaccine. The objective of the proposed study is to elucidate the role of CTB-INS on 
modulation of Smad2/3 for the induction of tolerogenic DCs. The central hypothesis 
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behind the proposed research is that CTB-INS fusion protein activates Smad2/3 signaling 
independently of TGFβ superfamily members for the induction of DC tolerance. This 
hypothesis is based on data from this dissertation that shows that CTB-INS stimulates 
Smad2/3 phosphorylation in the presence of TGFβ1 neutralization. Based on this 
observation we will test our central hypothesis by the following aim: 
 
Aim 2.1: Determine CTB-INS Induction of Smad2/3 Signaling Independently of 
TGF-β Superfamily Ligands 
The working hypothesis is that CTB-INS fusion protein activates Smad2/3 
signaling independently of TGFβ superfamily members for the induction of DC 
tolerance. This hypothesis will be tested by measuring Smad2/3 phosphorylation in 
human moDCs treated with CTB-INS, by Immunoblot analysis, after blocking all natural 
ligands of Smad2/3. We expect to detect Smad2/3 phosphorylation in DCs treated with 
CTB-INS in the presence of global blocking of TGFβ superfamily signaling, as assessed 
by comparing Smad2/3 phosphorylation in CTB-INS treated DCs with TGFβ superfamily 
treated DCs in the presence of neutralizing antibodies to the TGFβ superfamily members. 
It is anticipated that the future studies proposed here will reinforce the detection 
of these novel mechanisms by which CTB-INS mediates its tolerogenic functions. 
 
 
Conclusions 
The experimental findings documented in this dissertation demonstrate that CTB-
INS fusion protein vaccine induction of the immunoregulatory Smad2/3 signaling, TGF-
β1 superfamily cytokines and the biological activator of TGF-β1, integrin αvβ8, may 
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represent plausible mechanisms utilized by the vaccine in inducing immune suppression 
of human moDCs. These studies have revealed new insights involving the identification 
of immunoregulatory proteins defining the mechanistic action of CTB-INS, which is 
essential for the validation of CTB-INS safety and efficacy as a tool for the induction of 
tolerance in clinical applications for autoimmune diabetes. Investigations into the 
immunosuppressive strategies described here may also enhance the understanding of the 
modalities for tolerance induction in other autoimmune conditions. Every incremental 
understanding of the observed and supposed mechanism of tolerance induction in DCs is 
required given the intricate combination of intrinsic and extrinsic factors, such as 
environmental triggers or cell types, that add complexity to the development of 
autoimmune conditions. Solid understanding of the potential and defined mechanisms 
involved in tolerance and in the immune response, will increase the opportunities for 
developing safe and effective therapeutic strategies for autoimmune conditions (Van 
Brussel et al., 2014). For example, a novel finding documented in this dissertation is that 
TGF-β1 may not mediate IDO1 biosynthesis in human moDCs (Chapter 3). This finding 
may contribute to the understanding of the specific modulators of DC tolerogenicity that 
may be required in translational studies and clinical applications that require ex vivo 
generation of human tolerogenic DCs, especially tolerogenic DCs with IDO phenotype. 
Another significant finding produced by this dissertation relates to mechanism of CTB-
INS tolerance induction, and the interactions of the immunoregulatory molecules induced 
by CTB-INS in human moDCs.  It is clear that CTB-INS may utilize multiple 
mechanisms in mediating tolerance; the vaccine induces a number of immunomodulatory 
factors including, IDO1, activin-A, TGF-β1, integrin αvβ8 and Smad2/3 signaling, some 
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acting synergistically and others acting independently of each other. It is important to 
understand these distinctions since the CTB-INS fusion protein is not a natural product of 
biological systems. Therefore, further incisive characterization of the mechanistic 
functions of CTB-INS is required to expedite its clinical application for the therapy of 
T1D.  In Figure 5.1, the findings of the present study and prospective studies of 
immediate relevance are summarized. 
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Figure 5.1. Overall summary of experimental findings presented in this dissertation: 
Projected functions of integrin αvβ8 and TGF-β superfamily members in CTB-INS 
induction of immune tolerance in human dendritic cells. In signaling pathways (1, 2) CTB-
INS upregulates immunoregulatory proteins, TGF-β1, activin-A and integrin αvβ8 
expression in human monocyte-derived dendritic cells (moDCs). The presence of CTB-
INS fusion protein induces Smad2/3 signaling by increasing Smad2/3 phosphorylation. In 
pathway (3), increased TGF-β signaling appears unrelated to IDO1 biosynthesis in human 
moDCs. In signaling pathway (4), the mechanism by which CTB-INS suppresses DC 
activation is proposed to include stimulation of immunoregulatory proteins TGF-β1, 
activin-A and integrin αvβ8. Integrin αvβ8 is proposed to activate the latent complex of 
TGF-β complex to induce DC tolerance resulting in regulatory T cell (Treg) proliferation. 
a-TGF-β: Active TGF-β; L-TGF-β: Latent TGF-β; MHC: major histocompatibility 
complex molecules class II; TCR: T cell receptor. 
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